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Abstract 
Supply Chain Management (SCM) is the process of planning, implementing, and controlling 
the operations of the supply chain with the purpose to satisfy customer requirements as 
efficiently as possible. The sub-areas comprising a supply chain include: 
Forecasting/Planning, Purchasing/Procurement, Logistics, Operations, Inventory 
Management, Transport, Warehousing, Distribution, Customer Service etc. However, it is 
difficult to find a standard model of Supply Chain Management operating in the business 
community. Some business will refer to and manage their supply chains in a coordinated and 
all encompassing fashion, including the entire sub areas defined above.  
 
Eskayef  Bangladesh Ltd is one of the largest and fastest expanding pharmaceutical 
companies in Bangladesh. The company, which has its headquarters in Dhaka (the capital of 
Bangladesh), is also known as SK+F and is a part of the Transcom Group. SK+F Eskayef 
Bangladesh Limited was born from the old facilities of SmithKline & French in Bangladesh 
when the company was restructured to form GlaxoSmithKline in 2000. The company is 
involved in the manufacture and distribution of a diverse range of pharmaceutical products 
and therapeutic drugs. The main research questions of this study are as (i) What is the supply 
chain of Eskayef Bangladesh Ltd?(ii) How does Eskayef Bangladesh Ltd manages its supply 
chain? (iii) Does the supply chain management of Eskayef Bangladesh provide competitive 
edge?(iv)  What are the challenges in Eskayef’s supply chain?(v)  How the barriers could be 
overcome to bring competitiveness? In view of the context and research questions, the broad 
objective of this study is to analyse the supply chain of Eskayef Bangladesh Ltd. The specific 
objectives are as (i) To assess the extent to which the supply chain function of Eskayef has 
been operating;(ii) To understand the supply chain management of Eskayef;(iii) To evaluate 
the supply chain sustainability. (iv) To identify the barriers and challenges of the supply 
chain of Eskayef (v) To make recommendations for overcoming the challenges and to design 
an effective supply chain management. 
 
Given the increased attention of achieving effective supply chain management particularly in 
pharmaceutical industries around globe, this study is devoted assess the supply chain 
management of a leading pharmaceutical company in Bangladesh namely Eskayef 
Bangladesh Ltd. SCM is also important for achieving competitive advantages over the 
business rivals through a stronger relationship, closer and collaborative cooperation as well 
supplier development.  
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SCM also contributes in reducing cost of production and distribution through elimination of 
waste, compliance with standards and quality, promoting ethical sourcing, curbing unethical 
practices and diversity and equality in the workplace throughout the supply chain.  The study 
focused on the overall supply chain management of a fast growing pharmaceutical company 
in Bangladesh. The study highlighted the theoretical aspects of SCM and its potential 
advantages for a manufacturing company where there is intense competitive rivalry within 
the industry. Relevant models and theories will be adequately analyzed in this study. 
Information gathered through secondary sources and survey questionnaires has supported to 
the research on what the extent of SCM is effective and contributing to achievement of 
corporate strategy of the organization under the study.  Purposive and simple random 
sampling method are used to select 30 respondents who are directly involved in managing 
operations and supply chain of Eskayef Bangladesh Limited procurement, 60 from retailers 
and 30 from end customers.   
 
It is observed that 23.3% respondents have reported that they know the SCM very well 
followed by moderate knowledge (21.7%), sufficient knowledge (20%), somehow knowledge 
(20%) and 15% respondents have poor knowledge about SCM.  The results show that only 
25% respondents reported that they identified SCM as Data Collection, Supplier, 
Purchasing, Warehousing, Stocktaking, Distribution. While 46.7% respondents viewed SCM 
as Supplier Selection, Purchasing, Warehousing, Stocking, Distribution, 12% viewed SCM as 
warehousing and distribution and only 6% considered SCM as distribution. Multiple 
Response Analysis (MRA) is carried out to identify the benefits of SCM. Only 2.8% 
respondents identified no impact of SCM, 38.1% respondents reported high impact of SCM, 
31% viewed medium impact. In regards to heavy impact 20.7% respondents opined that SCM 
has heavy impact on the supply chain.    
Factor Analysis of the responses regarding the benefits of SCM reveals that shorter lead time 
has high mean (4.15) followed by reduced cycle time (3.97), Reduced waste (3.80), 
competitive advantage (3.83), reduced cost (3.78), greater supply chain visibility (3.72), 
reduced inventory (3.62) etc. From the component matrix it is found that 12 factors have high 
influence on the benefits of SCM. These are enhanced quality and service (0.772), greater 
supply chain visibility (0.757) reduced waste (0.753), effective business process (0.737), 
reduced cost (0.737), reduced cycle time (0.727), information sharing (0.698), improve 
responsiveness to customer requirements(0.680), competitive advantage (0.656), cooperative 
organizational relationships (0.6.50). Components 2 and 3 are not important as most of the 
factors have negative coefficients.  
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 About 30.0% respondents reported that SCM of SK +F is successful, 25% as very successful, 
21.7% as successful somewhat. Only 8.3% respondent reported that SCM is not successful at 
all, 15% reported as not successful. Regarding view on cost of EK+F products 43.3% retail 
respondents agreed that the cost is high as compared to other companies while 20.0% 
strongly agreed with high cost while 36.7% respondent are undecided on this issue. 
Regarding successfulness of SCM, 50% respondents from executives sample  reported it as 
very successful. 27.7% respondents identified SCM as successful, 16.7% reported as 
successful somewhat and only 6.7% as not successful. The results of field survey reveals that 
86.7% respondents has identified lack of coordination as a challenge to SCM while 80% as 
inventory management, 80% as order management, 33.3% as absent demand management, 
50% as human resource management, 20% as shortage avoidance, 53.3% as expiration 
management, 66.7% as warehouse management, 63.3% as temperature control and 66.7% as 
shipment visibility.  
SK+F produces high quality products. The retailers survey results show that 36.7% of the 
respondents rated products from EK+F as better, 31.7% as good, 18.3% as excellent as 
shown in Table:  . Regarding availability of EK+F products the survey results show that 
33.3% rated as good, 31.7% as better and 21.7% as excellent. With regards to affordability 
36.7 % respondents rated EK+F as good, 28.3% as excellent, 26.7% as better and 8.3% as 
moderate.  
 
Customer perception about SCM of EK+ F reveals that 46.7% respondents did not know it, 
33.3% as know somehow and 20% know well. Regarding quality of SK+F products 43.3% 
respondents rated as better, 36.7% as good, 13.3% as moderate and 6.7% as moderate. 
Regarding availability of products 36.7% respondents rated EK+F as better, 26.7% as good, 
16.7 % as moderate, 6.7% as excellent and 13.3% as poor. Regarding affordability of 
products 36.7% respondents rated EK+F as good, 307% as moderate, 23.3 % as better,  
6.7% as poor and 3.3% as excellent.  
Regarding frequency of use of products 46.7% respondents reported more frequently use 
while 53.3 mentioned occasionally use. Regarding rating of products 33.3% respondents 
rated SK+F as good, 26.7% as good, 23.3 % as moderate, 16.7% as excellent. Regarding 
perception SCM 46.7 respondents reported do not know, 33.3% as somehow know and 20% 
as know well.  About 65% of the retailer respondents reported supply and supplier risks, 
41.7% as organization and strategies risks, 68.3% as financial risks, 75% as logistic risks, 
38.3% as market issues, 68.33% as regulatory risks, 61.7% as inventory risks, 56.7% 
counterfeit risks. 
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About 80% of the executive respondents reported supply and supplier risks, 26.7% as 
organization and strategies risks, 90% as financial risks, 86.7% as logistic risks, 63.3% as 
market issues, 86.7% as regulatory risks, 90% as inventory risks, 76.7% as counterfeit risks. 
  
The pharmaceutical industry is one of the most technologically advanced sectors currently in 
existence in Bangladesh. It has grown in the last two decades at a considerable rate. The 
skills and knowledge of the professionals and innovative ideas of the people involved in this 
industry are the key factors for these developments. About 300 pharmaceutical companies 
are operating at the moment. Only 3% of the drugs are imported, the remaining 97% come 
from local companies. Positive developments in the pharmaceutical sector have enabled 
Bangladesh to export medicine to global markets. By overcoming the underlying obstacles 
this sector can develop more and can be an effective exporting sector of Bangladesh. 
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Chapter One: Introduction 
1.0 Prelude 
Supply Chain Management (SCM) is the process of planning, implementing and controlling 
the operations of the supply chain with the purpose to satisfy customer requirements as 
efficiently as possible. Supply chain management spans all movement and storage of raw 
materials, work-in-process inventory and finished goods from point-of-origin (POO) to point-
of–consumption (POC). SCM is a conscious and deliberate control, integration, and 
management of the business functions. SCM contributes and affects that supply flow through 
the business for the purpose of improving performance, costs, flexibility etc, which bring the 
ultimate benefits of the end customers or consumers.  The supply chain function includes 
many sub-areas such as: forecasting and planning, purchasing and procurement, logistics, 
operations, inventory management, transportation, warehousing, distribution, customer 
service etc. However, it is difficult to find a standard model of Supply Chain Management 
operating in the business community particularly in the pharmaceutical sector.  
 
Supply chain management (SCM) is the oversight of materials, information and finances as 
they move in a process from supplier to manufacturer to wholesaler to retailer to consumer. 
Supply chain management involves coordinating and integrating these flows both within and 
among companies. SCM is both a horizontal business function (i.e. managing the supply 
chain in a business) and a vertical industry sector (i.e. businesses involved in managing 
supply chains on behalf of their clients). A company may operate as a supply chain services 
provider within the vertical supply chain industry sector. But each of the clients serviced by a 
company will employ supply chain staff within their business operating on a horizontal basis 
across their organizations.  
 
All business needs to forecast and plan. To look forward and predict what will be required in 
terms of resources and materials in order to deliver their products or services to their 
customers in a timely manner. In this area we find SCM activities such as demand planning, 
inventory planning, capacity planning etc. The commercial part of the supply chain is 
purchasing or procurement. This is where a business identifies suppliers to provide the 
products and services that it needs to acquire in order to create and deliver its own service or 
product. Costs and terms of business are negotiated and agreed and contracts are formed.  
Thereafter the suppliers’ performance and future contractual arrangements will be managed 
in this area. This area of the business is sometimes referred to as purchasing, sometimes, 
procurement, buying, sourcing, etc. In its strictest definition purchasing is limited to the 
2 | P a g e  
 
actual commercial transaction and no more, whilst procurement includes the wider elements 
of the acquisition, including logistics and performance management.  
 
Figure 1.1: Basic Model of Pharmaceutical SCM 
 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
 
In its strictest definition logistics refers to the movement of goods or materials, whether 
inbound, through, or outbound. In some manufacturing businesses forecasting and planning 
will be found within a logistics department, in other businesses logistics will be exclusively 
managing the movement and transportation of goods and materials. Operations are a general 
management type activity ensuring that a business uses its resources effectively to meet its 
customer commitments. Inventory Management typically takes responsibility for both the 
replenishment of physical stock, the levels of physical stock, and of course storage and issue 
of physical stock. Stock may be materials and goods sourced from suppliers, work in 
progress, or finished goods awaiting sale/dispatch. Transport management can involve the 
control of a company owned fleet of vehicles, collecting, moving, or delivering materials and 
goods, or managing transport services sourced from a third party transport provider. 
Warehousing can involve the control of company warehouse space, or managing warehouse 
space sourced from third party providers. Distribution involves the physical distribution of 
the company’s products to the sub-distributor or directly to the customer base.  
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Most people do not recognize customer service as part of supply chain management, but it is 
to be considered as an important element. Because the final element is to check that the 
customers’ expectations were achieved, and manage any actions necessary to meet customer 
obligations and commitments. It is easily understandable that the success of a company 
depends a lot on their supply chain management system. The present success of many 
companies is the result of their successful supply chain management system. With the help of 
well organized SCM system a company takes the satisfaction from their suppliers and also 
from the consumers. Through SCM an organization can transmit properly what they are 
looking from the suppliers and marketers. The supply chain management of pharmaceutical 
products deserves high priority as it is related to the life and death of men and animals around 
the world. The present study is an attempt to analyze the supply chain management of a 
renowned pharmaceutical company in Bangladesh namely Eskayef Bangladesh Limited.    
 
1.1 A General View of Pharmaceutical Supply Chain 
 
The pharmaceutical supply chain is somehow different from other supply chains of physical 
goods because of its urgency, importance, storage, transportation, regulation etc. The 
following figures help understanding the SCM in pharmaceutical sector.  
  
Figure 1.2: Pharmaceutical Supply Chain 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
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Figure 1.3: Operations of Pharmaceutical Supply Chain 
 
Source: www.slideshare.net/pharma-chain/accessed on 28-12-2015. 
 
Figure 1.4: Typical Supply Chain Management - Main Components 
 
Source: www.slideshare.net/pharma-chain/accessed on 28-12-2015. 
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Figure 1.5: Flow of Goods and Information in SCM Processes 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
  
Figure 1.6: Supply Chain Management: Raw Materials to Consumers 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
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Figure 1.7: Extended Pharmaceutical Supply Chain Management 
 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
 
According to Whewell (2009), the pharmaceutical supply chain covers drug research, 
development, manufacture, distribution and application through a range of healthcare services 
and ancillary businesses that help effective functioning of these different stages. The 
pharmaceutical and healthcare industry is hugely complex because it involves so many 
markets, products, processes and intermediaries. It is also globally heavily regulated and used 
by everyone in life.  Ricci (2006) identified the importance of pharmaceutical companies 
taking control of the own distribution to maximize the potential of the different channels and 
to protect patients from errors or defects occurred during repackaging or relabeling.   
1.2 Statement of Problem: 
Eskayef Bangladesh Ltd is one of the largest and fastest expanding pharmaceutical 
companies in Bangladesh. The company, headquartered in Dhaka - the capital city of 
Bangladesh, is also known as SK+F and is a part of the Transcom Group. Eskayef 
Bangladesh Ltd was born from the old facilities of SmithKline & French in Bangladesh when 
the company was restructured to form GlaxoSmithKline in 2000. The pharmaceutical 
company is engaged in the manufacture and marketing of a wide range of therapeutic drugs, 
bulk pellets and animal health and nutrition products with annual sales surpassing 60 million 
US dollars. The company started its production of pharmaceuticals with the manufacture of 
generic products for the domestic market but has since moved into bulk products and the 
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veterinary market. SK+F currently manufactures and markets 28 different animal health 
products in 57 different dosage forms.  
With qualified, trained and skilled professionals on its staff and its unswerving standards of 
quality control, the company has distinguished itself as one of the most respected names in 
the pharmaceutical industry. Eskayef’s manufacturing facility has transcended the frontiers 
after the accreditation of UK MHRA (United Kingdom Medicines and Healthcare products 
Regulatory Agency). The dedicated cephalosporin plant of Eskayef Bangladesh Limited is 
the top class state-of-the-art manufacturing facility in Bangladesh Pharmaceutical industry. 
Eskayef Bangladesh Ltd. has been showing a significant outcome in exporting medicines to 
many countries. Eskayef Bangladesh Ltd. has started supplying medicines in 16 countries like 
Germany, UAE, Nepal, Bhutan, Sri Lanka, Myanmar, Vietnam, Ghana, Iraq, Indonesia, 
Kenya, Guatemala, Belize, Yemen, Macau and Somalia. The study is designed to analyse the 
supply chain management of the organization.  
 
1.3 Research Questions: 
The following research questions have been identified to conduct a meaningful study :   
(i) What is the supply chain of Eskayef Bangladesh Ltd? 
(ii) How does Eskayef Bangladesh Ltd manage the supply chain?  
(iii) Does the SCM of Eskayef Bangladesh Ltd provide competitive edge? 
(iv) What are the risks and challenges in Eskayef’s supply chain? 
(v)  How the barriers could be overcome to bring competitiveness? 
1.4 Objectives of the Study: 
 
In view of the context and research questions, the broad objective of this study is to analyse 
the supply chain of Eskayef Bangladesh Ltd. The specific objectives are as follows:  
 
• To assess the extent to which the supply chain function of Eskayef has been 
operating; 
• To understand the supply chain management of Eskayef; 
• To evaluate the supply chain sustainability.   
• To identify the barriers and challenges of the supply chain of Eskayef 
• To make recommendations for overcoming the challenges and to design an effective 
supply chain management. 
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1.5 Literature Review:  
It is widely accepted that the review of literature provides an understanding of the issues 
closely related to the research topic.  It also helps to justify the research under study and to 
find out the knowledge gap in the respective field. A number of books, articles, reports, web-
sites on supply chain management have been studied for this research work. It has been found 
that literature with specific focus on this sector in Bangladesh is not sufficient. However, a 
brief review of literature has been carried out.   
 
As the pharmaceutical marketplace confronts daunting challenges with various stakeholders 
demanding the pharmaceutical products to be affordable, strategic planning would be of the 
essence (Holdford, 2005; Birdwell, 1994). For the pharmaceutical industry, it assumes special 
significance as medical commodities would require to be delivered through the supply chain 
timely and within the reach and means of the consumers to meet their needs and satisfaction 
(Enyinda, 2009).  Supply chain is a set of players, processes, information, and resources 
which transfers raw materials, and components to finished products or services and delivers 
them to the customers. It includes suppliers, intermediaries, third-party service providers and 
customers. It also includes all of the logistics activities, manufacturing operations and 
activities with and across marketing, sales, product design, finance and information 
technology. 
 
A Supply Chain is that network of organizations which are involved through upstream and 
downstream linkages in the different processes and activities that produce value in the form 
of products and services in the hands of the ultimate customer or consumer (Lysons and 
Farrington, 2010). This definition highlights the key features of supply chain such as 
networks, linkages-upstream and downstream, processes, value and ultimate customers. 
Supply Chain Management is defined as the network of organisations that are involved, 
through upstream and downstream linkages, in the different process and activities that 
produce value in the form of products and services delivered to the ultimate consumer (Duby 
and Kumar, 2007). Supply chain management is the management of a network of retailers, 
distributors, transporters, storage facilities and suppliers that participate in the sale, delivery 
and production of a particular product (Chopra and Miendel, 2005). Handfield and Nichols 
(1999) defined pharmaceutical supply chain as “the integration of all activities associated 
with the flow of and transformation of raw materials through to the end-user, as well as 
associated information flows, through improved supply chain relationships to achieve a 
sustainable competitive advantage”. 
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SCM can be viewed as a set of activities to implement a management philosophy (Mentzer, 
J.T. et. al., 2001). They identified seven activities in this regard such as integrated behavior, 
mutually shared information, mutually shared risks and rewards, cooperation, the same goal 
and same focus on serving customers, integration of process, partners to build and maintain 
long-term relationship. Dubey and Kumar (2007) mentioned that effective supply chain 
management can impact and improve upon virtually all business processes, such as data 
accuracy, operational complexity reduction, supplier selection, purchasing, warehousing and 
distribution. The benefits of SCM are included as quicker customer response and fulfillment 
rates, shorter lead time, greater productivity and lower costs, reduced inventory supply 
throughout the chain, improved forecasting precision, fewer suppliers and shorter planning 
cycles. The pharmaceutical industry is a more than $500 billion global business that requires 
a tight, safe, and efficient supply chain. Modern pharmaceutical products rely on ingredients 
and materials from across the globe (Kaye, 2010).  
 
The line between a company’s internal operations and its external environment, in the 
opinion of Graves (2009), are becoming increasingly blurred. He stated that no area 
exemplifies this better than the supply chain where pharmaceutical manufacturers have to 
coordinate their own activities with those of partner organisations, healthcare providers and 
patients. He also noted that without a clear understanding of the context surrounding the 
process of delivering a drug to market, the chain can become a tangled web. Commenting on 
the challenges of supply chain management, Handfield and Dhinagaravel (2005) stated that, 
multiple events occurring on a daily basis are shaping the competitive and regulatory 
environment in which channel members operate their business. They pointed out that, 
regulators are demanding that wholesalers and manufacturers reveal pricing and are 
challenging the cost of pharmaceutical distribution. Market channels such as mail order, 
direct shipping and website pharmacies are also important competitive channels to consider. 
Another major driver of change, according to Handfield and Dhinagaravel (2005), is the 
increasing share of generics that are coming into the market, as some largest branded drugs 
go off patent. They observed that although the process of manufacturing and distributing 
branded and generic drugs is quite similar, the design of the distribution channel might be 
substantially different. They also noted that many generic companies are exploring 
relationships with Indian and Chinese manufacturers to market their products. Given these 
changes, it is little wonder manufacturers, wholesalers, pharmacies, hospitals, and other 
participants are bewildered with the array of different competitive challenges that face them. 
They indicated that the unfortunate result is, poor perception has been created at different 
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points in the supply and distribution chain; and channel participants have failed to 
communicate and work together to resolve the problems caused by this poor perception.  
 
Kiran Bala (2014) showed the evolution of Supply Chain Management as depicted in the 
following Table-1.1.  
Table 1.1: Era in the Evolution of Supply Chain Management 
Sl No. Era Description 
01 Creation Era The term supply chain management was first coined 
by an American industry consultant in the early 80s. 
However, the concept of supply chain in management 
, was of great importance long before in the early 20th 
century, especially by the creation of the assembly 
line. 
02 Integration Era This era of SCM was highlighted with development 
of EDI systems in the 1960s and developed through 
the 1990s by the introduction of ERP system. 
03 Globalization Era This era is characterized by the globalization of SCM 
in the organizations with the goals of increasing 
competitive advantage, creating more value added 
and reducing costs through global sourcing. 
04 Specialization Era ( Phase 
one) 
In the 1990s industries began to focus on core 
competencies and adopted  a specialization model. 
Companies abandoned vertical integration, sole off 
non-core operations and pout-sourced those functions 
to other companies.    
05 Specialization Era( Phase 
Two) 
Specialization within the supply chain began in the 
1980s with phase two- supply inception of 
transportation brokerages, warehouse management, 
and non-asset based carriers and has matured beyond 
transportation and logistics into aspects of supply 
planning, collaboration, execution and performance. 
06 Supply Chain (SCM 2.0) Web 2.0 is defined as a trend in the use of the World 
Wide Web that is meant to increase creativity, 
information sharing and collaboration among users. 
Source: Kiran Bala(2014)  
 
Svantesson (2009) has stated that pharmaceuticals, being high value goods, demand a safe 
process at all hubs in the chain, and security measurements must be harmonized and 
rigorously checked across the operating lanes with its sub-warehouses and on/off loading 
places. He further stated that the importance of utilizing as few on/off loading places and 
changes of transport mode is one of the challenges for a time effective and secure solution; 
this at a minimized cost level. According to Svantesson the market demands global solutions 
and customers are requesting the ability to order correct quantities and lower inventory levels. 
This situation brings a change to the order profile; with orders becoming smaller and 
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production changing accordingly. This is a challenge to the distribution of pharmaceuticals 
and consolidation possibilities that can meet with the lead time demand to the end customer 
are highly valuable. Svantesson noted that a change of routine in the supply chain can have 
dramatic effects if not properly implemented at all levels. With clear communication, the cost 
of change reduces dramatically. Global harmonization enhances the possibility of 
maximizing effects in a supply chain.  
 
The goals of the pharmaceutical supply chain, as indicated by Chopra and Miendel (2005), 
obviously emphasize regulatory compliance and safety of products, but also include 
leveraging information to be more responsive to the needs of consumers. They noted that, the 
unique nature of the supply chain for pharmaceuticals makes managing complex information 
for supply chain effectiveness challenging, but clearly the rewards for doing so are 
significant. They also indicated that, companies that excel in supply chain operations perform 
better in almost every financial measure of success. Supply chain excellence that improves 
demand-forecast accuracy leads to 5% higher profit margins, 15% less inventory, up to 17% 
stronger “perfect order” ratings, and 35% shorter cash-to-cash cycle times (VeriSign Inc., 20 
06). According to Chopra and Miendel (2005), many of these findings come from the 
Consumer Products (CP) Industry, where supply chain excellence means tightly aligning 
operations with consumer demand to become “demand driven”.  
 
Dubey and Kumar (2007) observed that, the shift to a demand-driven focus has been taking 
place within the CP industry for years. While perhaps leading the way is n implementing 
demand-driven processes, the CP industry is not alone in this interest or intent. They noted 
that leading pharmaceutical manufacturers also recognize the value of adopting demand-
driven supply chain practices and are benchmarking their organizations against CP 
manufacturers, and finding that their industry is generally behind the pace. They also 
indicated that the pharmaceutical industry is hindered by silos of information and a general 
lack of timely and reliable data as a result of historical business models and trading practices.  
 
Lambert et. al. (1998) identified eight SCM processes such as Customer Relationship 
Management (CRM), Customer Service Management(CSM), Demand Management, Order 
fulfillment, Manufacturing Flow Management, Supplier Relationship Management, Product 
Development and Commercialization, Returns Management. In the perception of Chopra and 
Miendel (2005), to robustly and reliably enhance patient safety and to become more demand 
driven, the pharmaceutical supply chain needs a ubiquitous technology framework that 
includes: Item-level data management; Standards for available data and how it will be 
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accessed and maintained; Data sharing infrastructure to accommodate cost efficient 
management and retrieval of data; Reliable trust environment to determine who can access 
information, if information provided can be certified as authentic, and what can be done with 
information provided or accessed. 
 
Most enterprises in the pharmaceutical supply chain have the ability to manage integrated 
business information at a transactional level (orders, shipments, payments, etc), which 
provides visibility into operational and financial events (Dubey and Kumar, 2005). They 
noted that, item-level data can extend this visibility to provide rich insight into the physical 
movement of particular products involved in these transactions and also enhance visibility of 
end-user demand, contract compliance, and reverse logistics. Achieving this level of 
visibility, as indicated by Dubey and Kumar (2005), requires unique identifiers in product 
labels or packaging. They further stated that, technologies such as barcodes enable packages 
to carry a unique identifier, and when coupled with an infrastructure of readers, can generate 
data about the events related to products. Commonly, this data would be stored in an event 
repository; either a single central item event repository or a network of local event 
repositories across geographies or business units within an enterprise.  
 
The Need for Standards In the opinion of Chopra and Miendel (2005), while item-level data 
management related to events within the enterprise may provide some incremental value, the 
potential for revolutionary value comes from the ability to link item-level data to events and 
observations outside the enterprise. In order to leverage item-level data across enterprises, 
standards are needed to ensure interoperability.  
 
According to Dubey and Kumar (2007), what is clear from early initiatives in item-level data 
sharing is that new types of data will be generated at unprecedented scale and will need to be 
exchanged in order to achieve measurable benefits across the supply chain. Conventional 
systems for business-to-business communications, as observed by Dubey and Kumar (2005), 
were not designed to manage this volume of data, and therefore will need to be augmented 
for item-level data management.  
 
The research work carried by Privett and Gonsalvez (2014) identified the top ten challenges 
of global pharmaceutical supply chain such as Lack of coordination, Inventory management, 
Absent demand information, Human resource dependency, Order management, Shortage 
avoidance, Expiration, Warehouse management, Temperature control, Shipment visibility. 
There are many examples now in the news about counterfeit drugs circulating in black market 
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channels and the places in which it is the biggest recurring problem is in the developing 
world where, in Africa and parts of Asia and Latin America, the proportion of counterfeit 
medicines has been estimated to be as high as 30%. Pharma companies have to manage 
incredibly complex supply chains and manage the operational challenges of working and 
interacting with huge numbers of suppliers contributing ingredients and components to drug 
production. And now they need to meet track and trace directives and comply with new 
serialization regulations that require inventory to be auditable as it moves through the supply 
chain. The article states that lack of coordination in the pharmaceutical supply chain is a root 
cause issue since it aggravates every other issue either directly or indirectly. The authors also 
highlight the opportunities for pharmaceutical companies that should drive future actions, 
policies and research and point out that measures should be taken to improve pharmaceutical 
delivery in regions that need it. This will make the global health challenge easier to take on 
and will help save lives.   
 
It is evident from different literatures (www.healthcarepackaging.com/trends-and-issues)  that ten 
steps are required to improve efficiencies in the pharmaceutical supply chain. In order to 
improve efficiencies and to cut cost in the pharmaceutical supply chain the following ten steps can 
contribute significantly: 
1. Cut out the middle man (wholesaler.) This will do three things: 
• Speed up the distribution process as the company will be delivering directly to the customer. 
• Cut costs by cutting out the middle man. 
• Sell more product: with better prices the companies will be more competitive and outsell 
competitors. 
2. Improvements in tracking product, which will cut down counterfeits and competitors copying 
product. This will help the pharmaceutical companies to stay ahead of the competition and be more 
efficient. 
3. Improve technology in the manufacturing process. This will help: 
• The products to be created quickly and efficiently. 
• Better technology will help product cost to be reduced and sold at a more competitive price. This 
will ensure dominance over competitors. 
• Upgrade manufacturing equipment and processes to make manufacturing product more efficient. 
4. Shift manufacturing outsourcing to new markets like India and China. This will cut costs as labor is 
cheaper here and products can be made more cost effectively. When this is done it will allow 
14 | P a g e  
 
pharmaceutical companies to be more competitive and cut costs in the manufacturing of their 
products. 
 
5. Quality control will be increased. This will ensure better quality products. Sales will increase with 
improved quality. There will be less wastage from substandard product that cannot be sold. When 
proper analysis of the quality of a product is done it can save disastrous recalls that hurt the company 
and can cost a substantial amount of money. With the pharmaceutical industry there is little room for 
mistakes and substandard product as peoples’ lives can be at risk. Additionally, the industry is highly 
competitive and sub-quality product can mean that contracts will move to competitors. 
 
6. Analyzing how money is being spent and where it is going is a factor. In order to cut costs an initial 
financial analysis must be done. It will then be possible to know where to cut costs and how to make 
budgeting better. 
7. Cutting costs in areas where there is wastage and money is not being used efficiently. There are 
always areas in any company that are not working as efficiently as they could. Too much money can 
be squandered in places where less investment would be equally effective. 
8.Supply chain analytics should be done. What do we mean by this term? It is when a company 
scrutinizes the supply chain process. They can assess which areas need to be improved and made 
more efficient. The supply chain is complex. Management deals with several suppliers and works on a 
global basis. This makes supply chain analytics challenging. Questions need to be asked in order to 
analyze the supply chain correctly: 
• Examine which suppliers are the best and most efficient: some suppliers are better than others. The 
more efficient the suppliers are the better the supply chain will work. 
• Different factors can affect the supply chain. The impact of various elements like weather or the rise 
and fall of fuel prices on the delivery system will affect cost of supply. 
• How much inventory to keep for certain products. This involves accurate analysis of supply and 
demand. Overstocking can cause wastage and force companies to lower prices to get rid of old stock 
in order to prevent heavy losses. Understocking can incur losses as the company will need to back 
order and sometimes need to compensate the customer for waiting. Worse scenario is that customers 
can go to competitors to get their order done on time, rather than wait for the back order. 
 
9. Once supply chain analytics have been conducted the pharmaceutical company can then apply the 
necessary changes needed to increase efficiency and cut costs in the supply chain. 
 
10. Examining the purchasing team in the company. The company must ensure that they are getting 
product of high quality but at the same time not spending too much on product from the suppliers. 
This may mean that they need to change suppliers to get better prices but still maintain quality. It is 
important to get detailed data from the purchasing section of the company to make the process more 
efficient and cost-effective. 
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The pharmaceutical industry in Bangladesh is one of the fastest growing sectors, which is on 
the brink of attaining self-sufficiency in meeting the country's domestic demand. Dominated 
mainly by the local manufacturers with their market share of around 87% and the rest by the 
multinational companies, the export earnings by the drug manufacturing firms now stand at 
approximately $27.54 million to more than 90 countries globally (Muktadir, 2011). This has 
been partly helped by the fact that Bangladesh, as a least developed country, currently enjoys 
some benefits in drug manufacturing as it is exempted by the Doha declaration from 
complying with patent protection until 2016 (Chowdhury, 2010). As this flexibility under the 
TRIPS (trade-related aspects of intellectual property rights) agreement will expire in a couple 
of years, this is likely to put the pharmaceutical industry in stiff challenges from its regional 
counterparts. As this industry in Bangladesh is playing such a vital role in country's economy 
through employment generation and boosting foreign exchange reserve, it is of utmost 
significance that the factors influencing the various dimensions of supply chain management 
(SCM) practices are looked into. The research questions set for this study are, therefore, two-
fold: first, what are the influencing factors of SCM practices as being currently observed? 
Second, how do these factors impact on one aspect of organizational outcome, i.e., such as 
customer satisfaction (CS) of the drug manufacturers in the pharmaceutical industry of 
Bangladesh? The objective of the study is to address these two questions. This is very 
pertinent as there is a significant lack of studies performed in this regard, particularly from 
the perspective of a developing country.  
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Figure 1.8: Supply Chain Management- Key Issues 
 
Source: www.slideshare.net/pharma-chain/accessed on 25-12-2015. 
 
A study of Fawcett, et al., (2008) identified benefits, barriers and bridges to effective supply 
chain management. the results of the study are summarized in the following Tables 1.2, 1.3, 
1.4:   
 
Table 1.2: Benefits of Effective Supply Chain Management 
 
Benefits Means  Rank % 5-7* 
Respond to customer requests 4.69 1 62.0 
On-time delivery 4.65 2 61.0 
Customer satisfaction 4.62 3 59.4 
Order fulfillment lead times 4.59 4 54.9 
Cost of purchased items 4.58 5 59.7 
Firm Profitability 4.51 6 53.7 
Handle unexpected challenges 4.49 7 59.2 
Inventory 4.48 8 53.0 
Overall product costs 4.38 9 51.0 
Productivity 4.31 10 52.0 
Overall product quality 4.16 11 44.3 
Transportation costs 3.88 12 37.9 
Market penetration 3.85 13 34.2 
Product innovation lead times 3.75 14 31.3 
Cost of new product development 3.43 15 24.2 
Source: Fawcett (2008) p. 43 
* 1 = not improved, 7 = greatly improved 
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Table 1.3 : Barriers to Effective Supply Chain Management 
   
Barriers Means  Rank % 5-7* 
Inadequate information systems 5.19 1 71.2 
Lack clear alliance guidelines 4.87 2 62.4 
Inconsistence operating goals 4.84 3 64.0 
Lack shared risks and rewards 4.83 4 65.6 
Processes poorly controlled 4.61 5 56.4 
Non-aligned measures 4.56 6 55.5 
Lack willingness to share information 4.56 7 56.1 
Organizational boundaries 4.49 8 52.4 
Measuring SC contribution 4.32 9 49.2 
Measuring customer demands 4.26 10 49.9 
Lack employee empowerment 3.80 11 34.8 
Lack resources for SCM 3.73 12 38.5 
 
Source: ibid, p. 43 
* 1 = not a barrier, 7 = serious barrier 
 
Table 1.4: Bridges to Effective Supply Chain Management 
 
Bridges Means  Rank % 5-7* 
Frequent communication 4.64 1 54.2 
Willingness to share information 4.59 2 55.0 
Use of cross-functional teams 4.37 3 47.2 
Shared expertise with suppliers 4.32 4 46.0 
Common goals 4.31 5 45.7 
Supply base reduction 4.21 6 42.8 
Senior management interaction 4.21 7 46.0 
Cross-functional processes 4.21 8 43.4 
Shared expertise with customers 4.14 9 41.6 
Customer selectivity 4.11 10 43.5 
Increase SC training 4.09 11 39.4 
Use of SC measures 4.08 12 42.3 
Use of consistence measures 4.05 13 39.8 
EDI linkages 4.02 14 43.2 
Clear selection guidelines 3.97 15 38.2 
Vendor managed inventories 3.86 16 36.2 
Use of total cost analysis 3.85 17 47.5 
Sharing risks and rewards 3.83 18 35.6 
Shared mission statement 3.80 19 36.3 
Clear alliance management guidelines 3.76 20 32.0 
Common operating procedures 3.74 21 27.5 
Use ERP/SCM software 3.36 22 25.3 
Use supply chain teams 3.31 23 24.8 
Use activity based costing 3.08 24 20.2 
    
 
Source: ibid, p. 43 
* 1 = not a facilitator, 7 = greatly facilitator 
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1.6 Significance of the Study 
 
Given the increased attention of achieving effective supply chain management particularly in 
pharmaceutical industries around globe, this study will seek to assess the supply chain 
management of a leading pharmaceutical company in Bangladesh namely Eskayef 
Bangladesh Ltd. Supply Chain Management addresses supply chain strategy, supply chain 
planning, procurement, logistics, asset management and product lifecycle management. 
Supply chain management is crucial tool for economy, efficiency and effectiveness in 
sourcing, manufacturing, processing, inventory management, logistic, transport, distribution 
and customer satisfaction. SCM is also important for achieving competitive advantages over 
the business rivals through a stronger relationship, closer and collaborative cooperation as 
well supplier development. SCM also contributes in reducing cost of production and 
distribution through elimination of waste, compliance with standards and quality, promoting 
ethical sourcing, curbing unethical practices and diversity and equality in the workplace 
throughout the supply chain.  The study will seek to assess the supply chain management in 
pharmaceutical industries. No comprehensive study has so far been done in this regard. The 
proposed research will attempt to fill up this gap. 
 
1.7 Scope of the Study 
 
The study will focus on the overall supply chain management of a fast growing 
pharmaceutical company in Bangladesh. The study will highlight the theoretical aspects of 
SCM and its potential advantages for a manufacturing company where there is intense 
competitive rivalry within the industry. Relevant models and theories will be adequately 
analyzed in this study. Information gathered through secondary sources and survey 
questionnaire will lend support to the research on what the extent of SCM is effective and 
contributing to achievement of corporate strategy of the organization under the study.   
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1.8 Diagram of Research Design 
The research process of this study is shown in Chart 11. 
Figure 1.9: Diagram of Research Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.9  Limitations 
The study has encountered a number of limitations which also discount the authenticity and 
reliability of the findings of the study.  Some of the limitations are as follows: 
(a) Time constraint is the main limitation of the study.  It was prescribed to submit the 
dissertation within one month. There should have sufficient time to conduct a study 
through a standard research protocol.  
(b) Budget constraint is also a vital lacking of this study. Sufficient budget allocation is 
required for collection of data and information from the primary sources. It is very 
crucial when the field study covers different cities.  
(c) Due to the two constraints mentioned above. The sample size of this study had been 
limited. Pharmaceutical supply chain has wider network both at home and abroad. 
The study is only limited to selected downstream partners. Only 60 respondents from 
retailers had been purposely selected from four major cities viz. Dhaka, Chittagong, 
                                                            
 
 
1 M. Zainul Abedin, A Handbook of Research (2nd Revised ed.; Dhaka: Book Syndicate, 
2005), p. 50. 
Statement of the Problem Setting of Objectives 
Literature Review • Methodology, 
• Variables Chosen,  
• Models Specifications. 
Data Collection, 
Processing, Factor 
Analysis.  
Estimation of data 
Interpretation 
 
Major Findings, 
Recommendations. 
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Khulna and Rajshahi. But only 30 consumers  had randomly selected from Dhaka city 
and 30 executives from the pharmaceutical company and distribution company under 
study had been selected.   
(d) Each and every respondent of this study was not well concerned about the whole 
supply chain system of the pharmaceutical supply chain.  
(e) The supply chain of Eskayef Bangladesh limited is not well documented. Therefore 
the researcher faced numerous difficulties to collect secondary data in relation with 
the supply chain system of Shrimp. No exclusive study had been found relating to 
pharmaceutical supply chain in Bangladesh.   
1.10 Time Frame 
December 2015-January 2016 
• Preparation of proposal  
• Completion of data collection and processing of data. 
• Completion of draft dissertation writing. • Editing and upgrading the draft.  
• Submission of the final dissertation. 
1.9 Thesis Plan (Breakdown of Chapters) 
 
The paper is structured as follows: following this introduction, a literature review is provided 
first, on the theories adopted in this study, and then on the dimensions of supply chain 
management practices and their impact on customer satisfaction demonstrating the theoretical 
framework of the study. Next, in the methodology section, instrumentation of the 
measurement items concerning the SCM practices and customer satisfaction is provided by 
mentioning the articles that have been reviewed for this purpose. Besides, how data were 
collected and analyzed is also stated. In the findings section, first, the reliability measures of 
the pertinent variables are presented. Factor analysis for the dimensions representing the 
SCM practices is then highlighted.  
The outline of chapters or organization of the dissertation is as follows: 
Chapter 1 : Introduction 
Chapter 2 : Methodology of the Study    
Chapter 3 : Overview of Pharma Sector and Company Profile  
Chapter 4 : Analysis of Data and Discussion of Findings  
Chapter 5 : Summary, Recommendations and Conclusion 
Bibliography, Appendices 
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Chapter Two: Methodology of the Study 
2.0 Prelude 
Methodology is an important part of any research work because without choosing and 
adopting an appropriate method a systematic investigation is not possible. Research 
methodology refers to the science of studying how research is conducted scientifically or how 
research problem is systematically solved (Kotahari, 1990). Method is originated from two 
Greek words such as ‘Meta’ and ‘Hodos’ meaning a way of conducting a work 
systematically. Research method is a process which consists of various techniques or steps of 
gathering data or information, processing and presenting of collected data and analyzing data 
(Aberdin, 2005). The method of research is a process of establishing a general proposition of 
gathering and weighing evidence (Hans Raj , 1987). 
The broad objective of this study is to evaluate the supply chain management of EK+F.  The 
study follows cross section data analysis techniques and tools for identified different aspects 
of SCM of EK+F. The survey method of field investigation is utilized and standard tools are 
applied to achieve the objectives of this study.  
Nature and Method of Study 
This dissertation has investigated the issues and challenges of the supply chain management 
of a leading pharmaceutical firm in Bangladesh.  This study is not only an exploratory but 
also an evaluative research. The Exploratory, Evaluative and Content or Documentary 
Analysis methods are applied to achieve the objectives of the study.  
Data Sources and Methods of Data Collection 
Primary Source  
The data from the primary sources have been gathered through field survey from the relevant 
respondents. Total number of respondents is 150. The respondents are retaile4rs, executives, 
consumers and medical services officer. This method is employed to assess the stakeholders’ 
opinions towards the process, benefits, views, knowledge, risks of the supply chain 
management of Eskayef Bangladesh Ltd. The suggestion tfor achieving an effective supply 
chain are also taken from the respondents.  The distribution of sample is shown in Table 2.1:  
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Data was collected from both staff and managers of Eskayef and Transcom Distribution 
Company, Retailers of Eskayef’s products, and end customers through structured interviews 
and administration of questionnaire. The sample distribution is as follows: 
 
Table 2.1: Distribution of Respondents 
 
Category of 
Respondents 
Frequency Location Types of 
Sampling 
Retailers 60 Dhaka = 15 
Chittagong =15 
Khulna = 15 
Rajshahi= 15 
Purposive 
Executives 30 Dhaka 
TDCL= 15 
EK+F = 15 
Purposive 
Consumer 30 Dhaka 
 
Random 
N 120 
 
Secondary Sources 
Secondary sources include published official statistics, reports, documents, laws, ordinances, 
books, articles, periodicals of different domestic and international agencies etc. Annual 
reports of Eskayef, different reports and statistics on the pharmaceutical sector in Bangladesh 
has been used.  
2.1 Data Analysis and Presentation 
 
Data processing: The collected data from secondary sources have been processed in an 
orderly manner so that it could be used for econometric modeling. The survey data from 
primary sources are arranged and scrutinized carefully on the basis of the completed 
questionnaire. Appropriate processing steps such as editing, coding, classification and 
tabulation are followed carefully. 
Analysis plan 
The collected data are analyzed by applying statistical tools and techniques such as 
correlation, Factor Analysis, Percentage Form etc. 
Data presentation: Some suitable data have been presented in graphs, charts, and pictogram.  
Interpretation of results: Results are interpreted suitably and unambiguously.   
23 | P a g e  
 
Data processing and models testing are performed by Ms-Excel, SPSS softwares.  
2.2 Techniques of Data Analysis 
 
To address the research objectives, this study utilizes a mixed methods approach comprised 
of quantitative and qualitative techniques. Questionnaire technique of survey method is used 
to collect primary data. Purposive and simple random sampling method are used to select 30 
respondents who are directly involved in managing operations and supply chain of Eskayef 
Bangladesh Limited procurement; 60 from retailers and 30 from consumers (end customers).   
 
A semi structured and pre-tested interview schedule has been used to collect data. Necessary 
correction, modification and alterations will be done accordingly.  Data has been collected 
through personal interview during December 2015-January 2016. Respondents were asked to 
indicate on a five-point scale ranging from 1 to 5.  
The responses of the respondents that were recorded in the interview schedule has been  
transferred into a master sheet for entering the data in the computer. The recorded data has 
been put into the computer for statistical analysis. The SPSS computer programme was used 
for analysis of data. Various descriptive statistical measures such as number and percentage 
distribution, range, mean and standard deviation will be calculated.  Simple tabular 
techniques will be used to explain the data. Minimum, maximum, mean, standard deviation 
and percentage for quantitative variables and T- test and percentage for qualitative variables 
are used to illustrate the results. Multiple response analysis, Factor analysis are also used to 
reflect the research objectives.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 | P a g e  
 
Chapter 3: Overview of Pharma Sector and Company Profile 
 
3.0 Overview of Pharma Sector in Bangladesh 
 
In Bangladesh Pharmaceutical sector is one of the most developed hi tech sector which is 
contributing in the country's economy. After the promulgation of Drug Control Ordinance - 
1982, the development of this sector was accelerated. The professional knowledge, thoughts 
and innovative ideas of the pharmacists working in this sector are the key factors for this 
developments. Due to recent development of this sector we are exporting medicines to global 
market including European market. This sector is also providing 95% of the total medicine 
requirement of the local market. Leading Pharmaceutical Companies are expanding their 
business with the aim to expand export market. Recently few new industries have been 
established with hi tech equipments and professionals which will enhance the strength of this 
sector. The pharmaceutical industries in Bangladesh are gifted with unparalleled potential to 
grow in the days ahead as they enjoy a number of competitive advantages, industry insiders 
said. 
The $700 million sector with more than 230 manufacturers is continuously expanding with 
new products to new international destinations. Among all the 50 LDC countries Bangladesh 
is the only country having quality pharmaceutical manufacturing base with marketing 
potential, and exporting to at least 80 destinations of the world, they said. 
The industry’s ability to comply with guidelines of quality assurance has put it on a solid 
base. Almost all companies are equipped with World Health Organization (WHO) Good 
Manufacturing Practice (GMP) standards. It has the ability to face competition from 
developing countries like India, China, Brazil and Turkey in its export markets due to strict 
quality compliance.  
 
However, experts in this sector suggest to form a banner within the 50 LDC’s of Asia-Pacific, 
Africa, Pharmaceutical Union (AAPU) amongst the Ministry of Health and Family Welfare 
(MoH&FW) or Ministry of Food and Drug Administration (DA) authorities to avoid re-
registration of companies and products within the member countries under this umbrella. The 
export value of pharmaceuticals is small but growing at 50 percent per year. Exports 
increased from $8.2 million in 2004 to $28.3 million in 2007, while export destinations 
climbed from 37 countries to 72 during the period. A good number of companies including 
Square Pharma, Renata and Eskayef have won accreditation from the UK Medicines and 
Healthcare Products Regulatory Agency (MHRA). 
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Incepta and Beximco Pharma have been accredited by EMEA (Austria) and the Therapeutic 
Goods Administration (TGA-Australia), respectively. These accreditations will allow them to 
enter the lucrative market with very competitive prices and standards as reputed global 
players. 
The most important indicator is the capability of the industry to achieve excellence and go 
beyond general international standards. Pharmaceutical export market can be categorized into 
three types, firstly, stringently regulated markets in USA, EU, UK, Australia, GCC which 
requires USFDA, UKMHRA, TGA, cGMP, GCC certifications and only a few from top ten 
companies can hardly afford these certifications. 
The mild regulated export markets which categories as second consisting the markets of 
Singapore, Sri lanka, Vietnam, Philippine also need ACTD formats along with bio 
equivalence clinical test reports of pharma products and these are critical procedures with 
time and money consuming factors and many of the mid level companies cannot afford. 
The final category is the less regulated export markets which are the only target markets 
remain in our hand to explore under the umbrella of AAPU. 
The products, which are registered by the DG of Drug Registration Authority (DRA), 
Bangladesh may be treated as registered within these countries, pharma official claimed. If 
required only Free Sales Certificates/Certificate of pharmaceutical products, Valid GMP 
Certificate, Product Approved Annexure, DML can be asked directly from our DRA 
Bangladesh by the importing countries MOH/FDA for the import of pharmaceutical products 
from Bangladesh. This will not only safe time and money but the current pharmaceutical 
turnover will grow many fold higher within shortest possible time before the implementation 
of WTO/TRIPS by the year 2015. Only 39 pharmaceutical manufacturing and marketing 
companies exported about Tk. 4.21 billion out of around 256 pharmaceutical manufacturers 
of Bangladesh. Moreover, pharma industry is now exporting active pharmaceutical 
ingredients (APIs) and a wide range of pharmaceutical products covering all major 
therapeutic classes and dosage forms to 79 countries. Besides, tablets, capsules and syrups, 
the country is also exporting high-tech specialized products like HFA Inhalers, CFC Inhalers, 
Suppositories, Nasal Sprays, Injectables, IV Infusions, etc. The packaging and the 
presentation of the products of Bangladesh are comparable to any international standard and 
have been accepted by them, said the official. 
 
According to the UKTI report 2010, the total size of the pharmaceutical market of 
Bangladesh was estimated to be $700 million in 2007. It also reports that the industry 
produced medication worth $715 million in 2007 with the market growing over 12pc 
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annually over the last half a decade and firms primarily focus primary on branded generic 
final formulations by using mostly imported APIs. According to a World Bank report of 
2008, about 80pc of the drugs sold in Bangladesh are generics and 20pc are patented drugs. It 
also reports that domestically Bangladeshi firms generate 82pc of the market in 
pharmaceuticals and locally based multinational companies account for 13pc, and the final 
5pc is imported. There are 240 registered pharmaceutical companies in Bangladesh where 
164 of these actively involved in the manufacture or marketing of pharmaceutical products. 
 
3.1 Drug Regulatory Authorities in Bangladesh  
 
A regulatory agency is a public authority or government agency responsible for exercising 
autonomous authority over some area of human activity in a regulatory or supervisory 
capacity. An independent regulatory agency is a regulatory agency that is independent from 
other branches or arms of the government. Two organizations regulate drugs and pharmacies 
in Bangladesh, one governmental and one semi-government, which are:  
The Directorate General of Drug Administration (DGDA)  
The Pharmacy Council of Bangladesh (PCB)  
 
The Directorate General of Drug Administration (DGDA): DGDA is the drug regulatory 
authority of Bangladesh, which is under the Ministry of Health and Family Welfare. DGDA 
regulates all activities related to import and export of raw materials, packaging materials, 
production, sale, pricing, licensing, registration, etc. of all kinds of medicine including those 
of Ayurvedic, Unani, and Herbal and Homoeopathic systems. 
 
The Pharmacy Council of Bangladesh (PCB):  
 
PCB was established under the Pharmacy Ordinance in 1976 to control pharmacy practice in 
Bangladesh. The Bangladesh Pharmaceutical Society is affiliated with international 
organizations International Pharmaceutical Federation and Commonwealth Pharmaceutical 
Association. The National Drug Policy (2005) states that the WHO’s current Good 
Manufacturing Practices (GMP) should be strictly followed and that manufacturing units will 
be regularly inspected by the DDA. Other key features of regulation are restrictions on 
imported drugs; a ban on the production in Bangladesh of around 1,700 drugs which are 
considered non-essential or harmful; and strict price controls, affecting some 117 principal 
medicines. 
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3.2 Local Market Overview  
 
The Bangladesh pharmaceutical marketplace is predominantly a branded generic 
marketplace. Pharmaceutical firms in Bangladesh can either sell to the private sector 
pharmacies, to the government and its public health care facilities, or to international 
organizations operating in Bangladesh (e.g. UNICEF). Bangladesh pharmaceutical industry is 
mainly dominated by domestic manufacturers. Of the total pharmaceutical market of 
Bangladesh, the local companies are enjoying a market share reaching around 97%, while the 
MNCs are having a poor market share. Out of the top ten pharmaceutical companies in 
Bangladesh, all are local pharmaceutical companies. The top two domestic manufacturers, 
namely Square and Incepta Pharma are having a combined market share of more than 30% of 
the total pharmaceutical market of the country.  
 
Bangladesh Association of Pharmaceutical Industries (BAPI) was instituted in 1972, since 
then BAPI playing a pivotal role in shaping up the industry. Association's member include 
large, medium, small, national and foreign companies who together are responsible for 
manufacturing 97% of the country's pharmaceutical production. 
 
3.3 Marketing Strategy of Pharmaceuticals in Bangladesh  
 
Marketing is the process by which companies create value for customers and build strong 
customer relationships in order to capture value from customer in return (Kotler, 2005). 
Marketing is the backbone of all industries. Though pharmaceuticals produce life saving 
drugs, they also need marketing. But their marketing is to some extent different from other 
industries. Some major characteristics of marketing sector are given below:  
 Their distributional channel includes invoice system, own distribution channel.  
 Medical representatives are the key persons in marketing.  
 For promotion, the groups such as doctors, surgeons are targeted.  
 Major promotional strategies include printed promotional materials, physical sample, 
and clinical materials.  
 Special incentives are given to the doctors. For example, the doctors are given 
honeymoon packages, the cost of which is borne by the pharmaceuticals.  
 
The field level executives are playing the imperative role for marketing division. Basically, 
they have taken the responsibility to market the products of their companies. So, the success 
of a pharmaceutical industry intensively depends on the efficiency and effectiveness of the 
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medical representatives. If an organization wants efficient employees in this section, he 
should to satisfy this representative. 
 
3.4 Drug Distribution  
 
Bangladesh’s drug distribution marketplace is composed of small independent pharmacies. 
This structure combined with an under-regulated industry, few firms manufacturing 
pharmaceuticals, and companies competing to sell branded generics based on brand names 
provides ample opportunity for the sale of low-quality drugs at higher prices. And this partly 
explains why the quality of drugs available for sale varies significantly in Bangladesh. The  
pharmacies sell from 200-22,000 types of medicines each. Each type of medicine has one to 
twenty five possible brands. Large pharmacies reported buying medicines according to sales 
trends – e.g. what sells the most. Medium and small pharmacies reported being linked with a 
medical doctor and thus sales are usually skewed towards that medical professional’s 
preferences. Most pharmacies are individual shops, though some chains are starting to 
develop, especially in urban areas. On average, each pharmacy visited has 10-50 
pharmaceutical firms that supply them medicines on a daily basis. 
For example, Beximco Pharmaceuticals has 1,200 people visiting pharmacies daily to take 
orders for drugs. None of the pharmacies visited will keep restocking any medicine that they 
consider a slow item. Small pharmacies report of keeping a medicine for a maximum period 
of six months.  
Although there are approximately 300,000 private pharmacies in Bangladesh, the government 
has only 26,000 pharmacies officially listed. The rest are illegal pharmacies as they have no 
license / licensed pharmacist on staff. Pharmacists have varying levels of education and many 
lack adequate training. For example, while the four large urban pharmacies visited each had 
one professional pharmacist (with four years of coursework), two of the medium-sized 
pharmacies visited had one person trained for one year along untrained coworkers working as 
pharmacists. Rural pharmacists can have high school graduates with approximately two 
weeks training. The Bangladesh Pharmacist Society is currently implementing the first phase 
of a three-phased program to improve the skills of pharmacists. The three-phased program 
should be complete in seven to eight years.  
While about 95% of the consumers in big pharmacies visited purchase medicines with a 
prescription, as few as 50% of people in medium and small pharmacies visited have a 
prescription. If people don’t have a prescription, they either come in and ask for a specific 
drug or come in and describe their ailment to the pharmacist who then makes a diagnosis and 
recommends a drug on the spot. Popular products include antibiotics of various levels, pain-
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killers, and gastric remedies. People purchase one to ten tablets or capsules at a time. The 
amount purchased depends more on the financial capacity of the consumer than on the 
required dose of medicine. 
 
Performance of pharmaceutical companies as a main player in pharmaceutical supply chain 
has significant effect on supply chain management efficiency. Risk identification and 
mitigating them in pharmaceutical companies not only can lead to process optimization, 
productivity increase and minimizing business risk, but also will help health systems to meet 
goals of supply chain management; Accessibility, Quality and Affordability. Many risks 
reported in this study are internal risks due to processes, people and functions 
mismanagement in a firm which could be easily managed by suitable mitigation strategies. 
Although only a few of the risks are external ones but their impact on business disruption 
have not studied. Therefore identifying their risk impacts of risks on business processes and 
functions and investigating mitigation strategies to manage them should be considered in 
future studies. 
 
API/Raw Material Production Plant: The major advancement of Bangladesh 
pharmaceutical sector has been occurred only in the production of finished products. 
Manufacturing of pharmaceutical products are vastly dependent on imported raw materials, 
as almost 90% of raw materials are now being imported. This dependency on imported raw 
materials is resulting in increased production cost of the finished products. Ultimately the 
competition to offer export prize is becoming tougher, which is one of the major challenges 
of pharmaceutical sector of Bangladesh. Setting up of a standardized Active Pharmaceutical 
Ingredient (API) plant is very essential. Local production of raw materials will greatly 
contribute to pharmaceutical export to extend export volume, and also can potentially 
contribute to the country’s economy.  
Some APIs are now produced within the country, and the range is increasing. The 
government and industry are jointly planning the development of an “API Park” at Bausia, 
about 40km from Dhaka, to concentrate API process development and production in a single 
location. Services and infrastructure (such as an incinerator and an effluent treatment plant), 
can be shared. Approximately 40 pharmaceutical businesses are likely to establish API 
production in the Park. There were hopes that the API Park can become operational in 2012.  
 
API Park  
Name of the project: API (Active Pharmaceutical Ingredient) Industrial Park Project Project 
Implementation Period: January 2008 to December 2012 Location of the project: Bausai, 
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Upazila-Gazaria, Dist: Munshigonj (37 Kms. aways from Dhaka by Dhaka-Chittagong 
highway) 
 
The regulatory authorities of Bangladesh: The documents provided by the Drug 
Administration of Bangladesh are not impressive; represent the poor status of drug regulatory 
authority of Bangladesh to the business community and to the regulatory authorities of 
importing countries. Besides, the website of DGDA is still lacking lot of necessary and up to 
date information, required and inspected by the business partners and regulatory authorities 
of importing countries.  
Regulated Markets: To register pharmaceutical products in regulated markets it requires 
highly standardized documents. There are regulations directed by the regulatory authorities of 
United States of America, European Union, Australia and Japan along with other highly 
regulated and semi regulated countries. To meet all their requirements sophisticated and 
accredited manufacturing plant, standardized manufacturing process, proper quality control 
and above all highly skilled professionals are required. It is tough to meet all the requirements 
by small pharmaceutical companies of Bangladesh.  
 
Medicine export should be emphasized to LDCs than any other countries: Some 
companies are aggressive to enter the highly regulated overseas markets, such as, USA, 
Australia, Europe, Canada, France, and Golf countries. But the practical observation is that 
getting export status to those countries requires huge investment in the manufacturing plant to 
achieve certification from different international drug regulatory authorities, highly 
sophisticated documentation, and huge initial capital investment. Actually the export volume 
to the highly regulated countries will not be easily feasible; rather we can perform pretty well 
and can potentially increase our export if the exporters become more attentive to LDCs. 
Among 50 LDCs, only Bangladesh has its strong fundamental and modern manufacturing 
base, hence we can easily share the drug market of rest of the LDCs. So, considering the 
practical situation, the LDCs should be the targeted markets of our pharmaceuticals, of 
course, side by side, moderately regulated and highly regulated markets may be explored 
gradually. However, we can establish joint-venture, tool manufacturing, and contract- 
manufacturing business with the companies of developed countries, not only for exporting 
medicines.  
Establishing Export cell by the govt./private Consultancy firms may promote Pharma 
export: Government can establish specialized Export Cell to promote exports of 
pharmaceuticals to grab and capitalize the huge export opportunities in LDCs. Some private 
Consultancy firms having experience and expertise in drug export professionally can be 
31 | P a g e  
 
engaged to assist the pharmaceutical companies who do not have the technical and expertise 
know-how to go through the entire process of export, or have lacking in documentation skills 
or even do not have the skilled man power to deal with the drug export. Thus, Consultancy 
firms can play a significant role to explore export to maximum countries, accelerate export 
activities, and to reduce the overall cost of export. Even some small companies having 
International Marketing Department (IMD) can explore the benefits of outsourcing by hiring 
Export Consultants to reduce its overhead expenditure and make a comparative study of cost-
benefit ration to justify having IMD.  
 
3.5 Important Departments of Management of Pharmaceuticals  
Human Resources:  
Human resources are people recruited in the organization and treated as the prime mover and 
an important element for success of any organization (DeCenzo & Robbins, 2005). The 
sector consistently creates job opportunities, especially for highly qualified people. 
Pharmaceutical companies are either directly or indirectly contributing largely towards 
raising the standard of healthcare and standard of living by enabling local healthcare 
personnel to gain access to newer products and also to latest drug information.  
Like other industries, pharmaceutical industry also believes that the human resources are 
most valuable asset for the organization. Pharmaceutical industry is making considerable 
investments in attracting and developing competent professional human resources. 
Pharmaceuticals not only foster entrepreneurship, but also consciously encourage 
entrepreneurship in their 
 
Training and Development:  
Training refers to instruction provided for a current job and has a rather narrow focus and 
should provide skills that will benefit the organization rather quickly. Development, on the 
other hand, has a broader scope and may not be focused on either the present or future job but 
more on the organization’s general long-term needs (Anthony, et al., 2003). Pharmaceutical 
industries are continuously striving to explore the necessary competences of the employees, 
especially the marketing executives to face the challenges of the competitive environment. 
They arrange different types of learning programs which are enforcing as a motivation too to 
upgrade necessary knowledge and skills of their employees. By interviewing the employees 
of different pharmaceuticals the researcher comes to know that they participated in various 
training programs that include: Pharmaceutical marketing situation beyond 2005, Company 
formation, regulatory compliance and company meeting, Industrial control and mechatronics, 
Continuous improvement and changing behavior, Presentation skills, General guidelines of 
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Standard Operating Procedure (SOP), Sanitation, hygiene and environment control, 
Maintenance of equipments, calibration and validation, Industrial automation, etc. 
Human Resources:  
Human resources are people recruited in the organization and treated as the prime mover and 
an important element for success of any organization (DeCenzo & Robbins, 2005). The 
sector consistently creates job opportunities, especially for highly qualified people. 
Pharmaceutical companies are either directly or indirectly contributing largely towards 
raising the standard of healthcare and standard of living by enabling local healthcare 
personnel to gain access to newer products and also to latest drug information.  
Like other industries, pharmaceutical industry also believes that the human resources are 
most valuable asset for the organization. Pharmaceutical industry is making considerable 
investments in attracting and developing competent professional human resources. 
Pharmaceuticals not only foster entrepreneurship, but also consciously encourage 
entrepreneurship in their organizational environment. This leads to innovation and creativity 
transformed into new products, services and new ways of doing things. To get most effort 
strom human resources, pharmaceutical industries implement programs like decentralization, 
job enrichment and job rotation. The extent of empowerment enjoyed by people at various 
levels of the organization enables each employee from the very bottom to the top, to 
contribute to the overall momentum of the companies.  
Data from the Labor Force Survey of 2005-2006 showed employment of 64,000 in the 
pharmaceutical sector of Bangladesh, of whom 3,000 were female. There has been strong 
growth in employment, driven mainly by growing domestic market sales, but also by 
significant growth in exports. 
Modern Drug Testing Laboratory: A major limitation of drug control authority of 
Bangladesh that also affects pharmaceutical export is unavailability of a modern, well 
equipped drug testing laboratory (DTL) with the engagement of sufficient and skilled 
pharmaceutical scientists. Due to lack of this, our drug control authority cannot monitor the 
quality of drugs manufactured by different pharmaceutical companies in Bangladesh. 
Moreover, foreign buyers and regulatory authorities raise question about the status of our 
drug testing laboratory, the central quality monitoring facilities of drug authority of 
Bangladesh. 
 
Bioequivalence Test Facility: Bioequivalence study of a product is a must for the 
registration of that product in many of the moderately regulated and regulated countries of the 
world. There is no standard facility for bioequivalence study in Bangladesh. In order to 
register a product, a pharmaceutical company has to carry out this test in foreign country by 
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spending of a huge charge. For this reason, many pharmaceutical manufacturers don’t show 
interest to register their products in foreign countries that require Bioequivalence study. It is 
relevant here to mention that BAPI and pharmaceutical exporters first felt the necessity of 
having Bioequivalence test facility in our country and they proposed and demanded to set up 
a modern Bioequivalence test center to the govt. for the promotion of pharmaceutical export. 
Custom Harassment in Sending Drug Sample: Considerable hazards or bureaucratic 
obstacles are confronted by the local pharmaceutical companies in sending samples abroad, 
to station or appoint representatives in foreign countries, in sending money for the purpose 
and doing other promotional activities. The customs authority of Bangladesh imposes 
restrictions in sending drug samples to the importing countries. Restrictions are being made 
on giving permission to send drug samples and also limiting the quantity of samples to be 
sent.  
3.6 Exports of Pharmaceutical Products  
Pharmaceutical exports from Bangladesh rose 15.65 percent year-on-year to Tk 553.3 crore 
in fiscal 2013-14 due to growing global demand, high quality products and competitive 
prices. Demand for Bangladeshi pharma products is growing in Asia, Africa and European 
markets as manufacturers follow international standards that ensure better quality. Exports 
grew 24 percent to Tk 478.4 crore in 2012-13 from the previous year, according to data from 
the Export Promotion Bureau. Bangladeshi medicine makers meet 98 percent of domestic 
demand and export to 88 counties. The country exported 30 pharmaceutical items in fiscal 
2013-14. The sector incurred losses in the first six months of last fiscal year due to internal 
problems which almost broke the supply chain down. 
The major problem is Bangladesh import raw materials due to lack of an API park in 
Bangladesh. India has API park and as a results it can offer competitive price in global 
markets compared to Bangladesh. As Bangladesh exports medicine to Europe which is 
known as stringent regulatory standards it gives impetus to our pharma industry and creates 
awareness among global customers particularly from emerging and developed markets. 
Although Southeast Asia and Africa are traditionally Bangladesh’s major markets for generic 
drug exports leading companies have now focused on advanced markets. Top companies 
have registered products in countries like Netherlands, Latvia, Azerbaijan, Costa Rica, 
Estonia and Lithuania.  
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3.7 Company Profile 
3.7. 1 Introduction 
Eskayef Bangladesh Limited, a successor of world-renowned multinational pharmaceutical 
company, SmithKline & French (SK&F), USA was acquired by TRANSCOM in 1990 in the 
wake of the merger between SmithKline & French, USA and Beecham, UK. TRANSCOM is 
one of the leading and fastest growing business conglomerates in Bangladesh. Like 
TRANSCOM, not many industrial groups in Bangladesh can claim a history of continuous 
business pursuits stretching back over 100 years. Over the time, its early industrial ventures 
have moved over to businesses involved in high-tech manufacturing, international trading and 
distribution, forming strong ties with a host of blue chip multinational companies. 
 
After the acquisition of SK&F by TRANSCOM, the new company was named – Eskayef 
Bangladesh Limited and it has subsequently culminated to become one of the leading 
pharmaceutical companies of Bangladesh. Rapid business growth since its inception have 
propelled Eskayef to a position of eminence among the pharmaceutical companies operating 
in Bangladesh today. 
Table 3.1: Eskayef Bangladesh Limited at a Glance 
Company name Eskayef Bangladesh Limited 
Logo 
 
Slogan Excellence through quality 
Type Private Limited Company 
Acquisition from SmithKline & French, USA 
Company inception 1990 
Ownership Transcom Group 
Chairman Mr. Latifur Rahman 
Managing Director & Chief 
Executive Officer Mrs. Simeen Hossain 
Employees 4000+ 
Business Pharmaceutical Finished Products, Bulk Pellets, Animal Health & Nutrition Products 
Distribution Transcom Distribution Company Limited (TDCL) 
Web address www.skfbd.com 
Source: www.skfbd.com accessed on 10-1-2016 
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3.7.2 Major Landmarks: 
Eskayef Bangladesh Limited, a successor of world-renowned multinational pharmaceutical 
company, SmithKline & French (SK&F), USA was acquired by TRANSCOM Group in 
1990. After the acquisition, the new company was named ‘Eskayef Bangladesh Limited’ and 
it has subsequently culminated to become one of the leading pharmaceutical companies in 
Bangladesh. Rapid business growth, since its inception has propelled Eskayef to a position of 
eminence among the pharmaceutical companies operating in Bangladesh today. Owing to its 
qualified, trained and skilled professionals and through its unswerving standards of quality 
control, Eskayef is now one of the most respected names in the pharmaceutical industry of 
Bangladesh. The major landmarks of the company in different years have been shown in the 
table:  
Table 3.2: Major Landmarks of Eskayef Bangladesh Limited 
Year Landmarks 
1979 Incorporation as a subsidiary of SmithKline & French, USA 
1990 Acquisition of Smithkline & French (SK&F), USA by Transcom 
1999 Introduction of Pellet Technology in Bangladesh 
2001 Acquition of old Squibb plant at Tongi by Transcom Group 
2001 Commencement of Animal Health & Nutrition Division 
2006 Inception of state of the art Tongi plant 
2008 Achievement of UK MHRA accreditation 
Initiation of Cepha Plant 
2010 Starting af Novo Nordisk's Insulin Manufacturing 
2010 Attainment of TGA Australia accreditation 
2011 Attainment of VMD UK accreditation 
2013 Accomplishment of EU GMP accreditation and Launching of Eye 
Care Project 
2014 Achievement of UAE GMP accreditation 
     Source: www.skfbd.com accessed on 10-1-2016 
Eskayef  Bangladesh Ltd. is currently exporting its quality finished products to 19 countries 
across 4 continents as the part of the mission of Growing More Global. In the year 2012, 
Eskayef has entered into the regulated market with excellence through quality. Eskayef is 
among the pioneers to export products to Australia, United Kingdom, Netherlands and 
expanding its business horizon to other European countries. 
 
The International Business Department has put a sincere business drive in 2012 and 
registered a remarkable growth of 54% over the year 2011. The technical knowhow, vision 
and innovative ideas of the professionals working in the company are the key factors for this 
achievement. In the coming years, Eskayef is aiming to be a global pharmaceutical company. 
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The company exports its products in 23 countries of the world through our distribution 
partners. 
Table 3.3: Overseas Markets of EK+F 
Region Countries 
Europe Netherlands, United Kingdom 
Australia Australia, Fiji 
Africa Algeria, Burundi, Cameroon, Kenya, 
Niger, Somalia, Uganda 
Asia Afghanistan, Iran, Myanmar, Nepal, 
Philippines, Sri Lanka, UAE, 
Vietnam, Yemen 
Source: www.skfbd.com accessed on 10-1-2016 
Table 3.4: Relative Market Position of Eskayef 
SL COMPANY 
Value (Cr) 
TK Share Growth(% 
Total Pharma Market 8,047.85 100.00 24.63 
1 SQUARE 1,511.53 18.78 22.03 
2 INCEPTA PHARMA 740.96 9.21 29.17 
3 BEXIMCO 703.86 8.75 33.14 
4 OPSONIN PHARMA 407.84 5.07 28.81 
5 RENATA 391.56 4.87 27.86 
6 ESKAYEF 386.34 4.80 22.07 
7 ACME 342.57 4.26 16.55 
8 A.C.I. 337.89 4.20 21.91 
9 ARISTOPHARMA 324.79 4.04 24.55 
10 
DRUG 
INTERNATIONAL 292.54 3.63 17.08 
Source: http://medibd.blogspot.com/2011/11/top-50-pharmaceutical-company.html 
3.8 Mission, Vision and Quality Approach 
 
Mission 
To manufacture and supply products with quality and excellence and to contribute to improve 
the population’s health & well-being. 
Vision 
To lead the national pharmaceutical market, to be recognized as a multinational conglomerate 
from Bangladesh and stand out as a model of efficiency & trust to our collaborators, 
consumers, health care professionals & society. 
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Quality Approach 
Eskayef  believes that pharmaceutical business is built solely on the blocks of trust and it 
takes perseverance for a pharmaceutical business entity to earn the trust of the people. Many 
global best practices are being cultured in the everyday activities of Eskayef, which are 
contributing in a big way to shape up its future & earning people’s trust. "For a holistic 
working philosophy, the company is governed by three fundamental values: Total Quality 
Management, Business Ethics and Societal Commitment" 
 
Eskayef is a quality driven and scientific information based company. The EU GMP 
(European Union Good Manufacturing Practice), UK MHRA (Medicines and Healthcare 
Products Regulatory Agency of UK), TGA Australia (Therapeutic Goods Administration of 
Australia), UAE GMP (United Arab Emirates Good Manufacturing Practice) and VMD UK 
(Veterinary Medicines Directorate of UK) approved state-of-the-art pharmaceutical 
manufacturing facility has further reinforced high standards of quality, safety and efficacy of 
Eskayef products. The company is currently exporting medicines to many countries across 
four continents, including some highly regulated markets in Europe and Australia. Eskayef 
Bangladesh Limited continues the journey of pellets development with pride and perfection 
since 2001. In addition to the consumption in the domestic market, Eskayef is successfully 
exporting its pellets to Australia, Indonesia, Iran, Myanmar, UAE and Vietnam. 
 
Since its inception on 2001, across the nation Agrovet Division has been playing an 
important role in the business sectors of Poultry, livestock & Aquaculture. Quality premixes 
along with wide range of prominent therapeutic & nutritional brands are its major strengths. 
Recently commissioned Injectable brands have already attained its fame for premium quality. 
It is also marketing imported poultry & aquaculture products from world’s top class 
companies. Since 2005 it has emerged as the pioneer exporter of animal health products from 
Bangladesh.  
 
Eskayef believes that pharmaceutical business is built solely on the blocks of trust and it 
takes perseverance for a pharmaceutical business entity to earn the trust of the people. Many 
global best practices are being cultured in the everyday activity of Eskayef, which are 
contributing in a big way to shape up its future & earning people’s trust. Eskayef Bangladesh 
Limited, owing to its qualified, trained and skilled professionals and through its unswerving 
standards of quality control, Eskayef is now one of the most respected names in the 
pharmaceutical industry of Bangladesh. 
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3.9 Supply chain management of Eskayef Pharmaceuticals Ltd.  
The pharmaceutical supply chain is the means through which prescription medicines are 
delivered to patients. Pharmaceuticals originate in manufacturing sites; are transferred to 
wholesale distributors; stocked at retail, mail-order, and other types of pharmacies; subject to 
price negotiations and processed through quality and utilization management screens by 
pharmacy benefit management companies (PBMs); dispensed by pharmacies; and ultimately 
delivered to and taken by patients. There are many variations on this basic structure, as the 
players in the supply chain are constantly evolving, and commercial relationships vary 
considerably by geography, type of medication, and other factors. The pharmaceutical supply 
system is complex, and involves multiple organizations that play differing but sometimes 
overlapping roles in drug distribution and contracting. This complexity results in considerable 
price variability across different types of consumers, and the supply chain is not well 
understood by patients or policymakers. Increased understanding of these issues on the part 
of policymakers should assist in making rational policy decisions for the Medicare and 
Medicaid programs.  
 
3.9.1 Supply chain stages of Eskayef Bangladesh Ltd: 
  
A supply chain consists of all parties involved, directly or indirectly in fulfilling customer’s 
requirement. It includes not only manufacturers and suppliers, but also transporters, 
warehouses, retailers and customers themselves.  
The key players and their financial relationships-  
¾ Pharmaceutical Manufacturers:  
¾ Wholesale Distributors:  
¾ Pharmacies:  
¾ Pharmacy Benefit Managers (PBMs) 
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Distribution channel of EK+F is shown in Figure: 3.1 
Figure 3.1: Distribution Channel of EK+F 
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3.10 Suppliers of EK+F:  
Major raw materials of EK+F  include many different types of dyes and chemicals. Suppliers 
of this company are Weifang Shengtai, MSM Prai Berhad, Sainor, Magaldrate, Active Fine 
Chemicals Ltd, MEGAWIN, Implex Corporation, Drug International Ltd etc. provides these 
raw materials. Plant & machineries are imported from India, U.K, China, Taiwan, Korea, 
Japan by EK+F. 
Table 3.4: Source of Major Raw Materials Procurement 
Name of Items Suppliers Quantity(Kg) 
Dextrose Weifang Shengtai Pharmaceutical Inc., is a 
leading producer of pharmaceutical-grade 
glucose in China. The company estimates that 
its pharmaceutical glucose products account 
for about sixty percent of the total China 
pharmaceutical glucose market.  
570000 
Sugar 
MSM Prai Berhad (formerly known as 
Malayan Sugar Manufacturing Company 
Berhad) operates the Prai sugar refinery in 
Penang. Located on the northwest coast of 
Peninsular Malaysia, the facility is the 
country’s largest sugar refinery with an annual 
production capacity of 960,000 tonnes of 
refined sugar, accounting for up to 86% of 
MSM’s total production capacity. 
1500000 
Omeprazole Pellets SAINOR Established in the year of 2005, and 
today it is one of the fastest growing 
organizations in the niche area of drug loaded 
pellets.  With combination constant product 
innovation and adaptation to suit the spirit and 
intent of customer requirements, constructed 
according to WHO GMP Specifications. The 
people behind this organization are young 
technocrats with an ambition to make 
SAINOR one of the topnotch companies in 
INDIA, to make a mark in the NATIONAL 
SECTOR and became a force through exports 
to Global Markets.  
153000 
Magaldrate SPI Pharma is a global leader serving over 55 
countries in the manufacture and marketing of 
antacid actives, excipients, taste-masking 
technology, drug delivery systems for tablets, 
fast-dissolve technologies, chewables, 
lozenges, and a variety of other patient-
friendly dosage formats. SPI also specializes in 
drug development services, delivering in-vitro 
data packages in CTD Module 3.2 format.  
128800 
Source: EK+F Main Office, Dhaka 
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 3.11 Manufacturing Facilities: Located at Tongi ( outskirts of Dhaka city), Mirpur and 
Bhulta, Rupganj EK+F’s manufacturing site is spread over an area of 20 acres which houses a 
number of self-contained production units including oral solids, metered dose inhalers, 
intravenous fluids, liquids, ointments, creams, suppositories, ophthalmic drops, injectables, 
nebulizer solutions etc. The bulk drug unit for producing paracetamol is also located within 
this site. EK+F has its own utility infrastructure to ensure adequate generation and 
distribution of purified water at all times.  
The manufacturing and packaging facilities have been designed to minimize generation and 
maximize containment of dust particles using closed transfer system and clean in place 
facility. All practicable measures have been taken to ensure that members of the staff are not 
exposed to unacceptable concentrations of dust particles. Process area, cubicles, storage area 
have been connected to vacuum dust cleaning. The design of the plant ensures automated 
materials handling systems and multilevel designs to enable gravity feed between processing 
stages. The building design has also allowed maximum engineering maintenance access 
without entering into the production areas.  
 
3.11.1 Warehousing: Storing of raw and packaging materials to meet the requirements of 
production and also storing and dispatch of finished products as per concept of Good Storage 
Practice of pharmaceuticals per concept of Good Storage Practice of pharmaceuticals. After 
manufacturing, EK+F stores these products in their warehouses. 
 
3.11.2 Depots: Then, from the storehouse TDCL distribute these products to its depots inside 
and outside Dhaka. EK+F can achieve responsiveness to customers demand by locating large 
inventory in the depots to the customers. This distribution centers distribute them to a variety 
of customers, including pharmacies (retail and mail-order), hospitals, and long-term care and 
other medical facilities (e.g., community clinics, physician offices and diagnostic labs). EK+F 
is successfully operating distribution of medicine throughout 54 districts out of 64 districts in 
Bangladesh.  
 
3.11.3 Retailers (Pharmacy): After that, EK+F provides the medicine to many pharmacies 
all over the country. Pharmacies are the final step on the pharmaceutical supply chain before 
drugs reach the consumer/patient. Pharmacies purchase drugs from distribution centre and 
MPO’s and occasionally directly from manufacturers, and then take physical possession of 
the drug products. After purchasing pharmaceuticals, pharmacies assume responsibility for 
their safe storage and dispensing to consumers. Pharmacy operations include maintaining an 
adequate stock of drug products, providing information to consumers about the safe and 
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effective use of prescription drugs, and facilitating billing and payment for consumers 
participating in group health benefit plans.  
 
3.11.4 Consumers: The ultimate destination is consumer. For different promotional 
activities, the doctors prescribes medicine to the customers and customers can get the 
medicine from many pharmacies and drug stores of hospitals.  
 
3.12  Push/Pull view of the supply chain of Eskayef Bangladesh Ltd.:  
All the processes in a supply chain fall into one of two categories depending on the timing of 
EK+F’s execution related to end customer demand. With pull process, execution is initiated 
in response to customer order. With push process, execution is initiated in anticipation of 
customer orders. Therefore, at the time of execution of a pull process, customer demand is 
known with certainty, whereas at the time of execution of a push process, demand is not 
known and must be forecasted. Push processes operate in an uncertain environment because 
customer demand is not yet known. Pull processes operate in an environment in which 
customer demand is known.  
Here, EK+F Pharmaceuticals execute all process in the customer order cycle before the 
customer arrives. So, all the manufacturing activities procurement cycle, replenishment cycle 
are performed in anticipation of demand and are thus push process. The goal of 
replenishment cycle is to ensure product availability when a customer order arrives. In fact, 
raw materials such as chemicals are often purchased six to nine months before customer 
demand is expected. EK+F produce the medicine three to six months before the point of sale. 
And all processes that are part of the customer order cycle are pull process. The order 
fulfillment takes place from product in inventory that is built up in anticipation of customer 
orders. EK+F is often constrained by inventory and capacity decisions that were made in the 
push phase. The processes in the EK+F Pharma supply chain break up into pull and push 
processes, as shown below: 
 
 
 
 
 
 
 
 
SK+F 
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3.12.1 Design option for a distribution network of EK+F: Distribution refers to the steps 
taken to move and store a product from the supplier stage to a customer stage in the supply 
chain. Distribution is a key driver of the overall profitability of a firm because it affects both 
the supply chain cost and the customer experience directly. 
 
3.12.2 Manufacturer storage with carrier delivery: Here, EK+F follows “Manufacturer 
Storage with Carrier Delivery” design as distribution network system. Under this option, 
inventory is held by EK+F  in their depots and store house, and then distribute the medicine 
to many pharmacies all over the country by the delivery van of EK+F. Then, the customers 
get the medicine through these pharmacies. Pharmacies as retailer carry no inventories. 
Information flows from the customer, via the retailers to EK+F. 
 
Figure 3.1: Product Flow and Information Flow 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.13 Performance Characteristics of manufacturer storage with carrier delivery of 
EK+F: The supply chain strategy determines how the supply chain should perform with 
respect to efficiency and responsiveness. The supply chain of EK+F must use three logistical 
and three cross-functional drivers to reach the performance level the supply chain strategy 
dictates and maximize the supply chain profits. The ideal supply chain will emphasize 
Factory
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efficiency but also maintain an adequate level of responsiveness. The biggest advantage of 
manufacturer storage with carrier delivery is the ability to centralize inventories at EK+F. It 
can aggregate demand across all retailers that it supplies. The key issue with regard to 
manufacturer storage with carrier delivery is the ownership structure of the inventory at the 
EK+F. The benefits from centralization are highest for high value, low demand items with 
unpredictable demand. 
Table 3.5: Factors and Performance 
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3.14 No of Foreign Suppliers of Raw Materials and Major Items of Procurement 
Table 3.6: Number of Foreign Suppliers 
Year No. of Foreign 
Suppliers 
% increase 
2010 180 - 
2011 185 2.78 
2012 204 10.27 
2013 270 35.35 
2014 356 31.85 
2015 375 5.33 
Source: Eskayef Main Office, Dhaka 
 
Table 3.7:  Total Import Raw Materials during last Five Years. 
 
 
Year Imports  
( in Million US$) 
Growth Rate 
(%)  
2011 22.30 - 
2012 25.45 14.13 
2013 32.27 26.80 
2014 34.61 7.25 
2015 41.02 15.52 
Source: Eskayef  Corporate  Office, Dhaka 
 
Table 3.8:  Yearly Sales of during the last Five Years. 
 
 
Year Imports  
( in Million US$) 
Growth Rate 
(%)  
2011 451 - 
2012 573 14.13 
2013 618 26.80 
2014 740 7.25 
2015 855 15.52 
Source: Eskayef Corporate  Office, Dhaka 
 
 
3.15 Steps of Raw Materials Import Procedure  
Eskayef Bangladesh Limited has been maintaining the following steps for imports of required 
raw materials: 
1. Material Requirements Planning (MRP) 
MRP is a planning and inventory control system used to manage manufacturing 
processes. It provides answers for questions e.g. what items are required? How much 
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quantity is required and when are they required? Procurements of required raw 
materials usually start once they received MRP.  
 
2. Block List 
After getting MRP they have to apply for block list permission and it is must for each 
imported raw materials which is usually held twice in a month and it is authorized by 
the drugs regulatory department. 
 
3. Block List Amendment 
If the price varies from the block list they have to apply for the amendment usually 
takes seven working days or more for low price amendment and if they require high 
price amendment then they have to wait for the next block list meeting. 
 
4. Pricing 
After that they have to ask price from their approved sourced through their local 
agent, sometimes they collect the price directly from the supplier if there is no local 
agent. 
 
5. Vendor Selections 
They usually select the vendors carefully after checking price feasibility and other 
compatibilities 
 
6. Asked for Indent or Proforma Invoice 
After the proper selection of source they have to ask for the Indent or PI which is 
issued by the local agent or supplier or manufacturer. 
 
7. Approval from Quality Assurance 
They send the PI/Indent to the QA department through fax/e-mail for getting approval 
from General Manager of QA department. 
8. Purchase Order 
Once they received the approval they have to make purchase order in ACCPAC. 
9. Apply for Cover Note 
They should apply for cover note which usually takes two or three working days. 
10. L/C Proposal: In the mean time they have to make L/C proposal which must be signed by 
Import Manager and General Manager (Commercial) 
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11. L/C Typing 
After that they have to arrange for L/C typing. 
12. Signing 
Once the typed L/C is received at their end, they should check it very carefully and do 
the correction where there is any mistake found and then they have to send it for 
signing. 
13. Sending L/C Application to Bank 
Then they arrange to send the signed L/C application to the bank with keeping proper 
copies in their respective files. 
14. Draft L/C 
After sending L/C application to the bank they have to wait for draft L/C which 
usually takes two working days. 
15. Final L/C Confirmation 
They have to confirm L/C by sharing it to the suppliers, after deleting or adding 
clause in accordance with suppliers they have to arrange it to swift and share it to the 
supplier.  
16. Following up with the Source/Supplier 
They should follow up regularly with the suppliers to get the materials on due time. 
17. Document Processing  
Once the shipment has been made they have to process the shipping documents as 
follows: 
(i) Drug Clearance: After getting the shipping documents they have to 
apply for drug clearance to the drugs regulatory department anf 
usually it takes two days to get permission from the drug 
authorities.  
(ii) Marine Policy: They usually apply to the Insurance Department to get 
policy and a single day is required for getting it.  
(iii) Shipping Guarantee ( for Air Shipment): if the mode of shipment is by 
air then they should apply for shipping guarantee to the bank with 
the non-negotiable copy and the application should be duly sign by 
their authority. 
(iv) Retirement(for sea shipment): if the material is shipped by sea then 
they have to apply to the bank for teturing the original documents 
after getting the conformation from the bank and application of 
retirement must be properly signed by our respective authorities. 
48 | P a g e  
 
(v) Customs Clearance: Once they received all the documents which is 
required they usually go for customs clearance and arrange to take 
over customs documents to their C & F agent accordingly.  
18. Receiving and Inspecting Materials: Receiving Report is issued after getting the 
RM at their warehouse and after receiving the RM their QC or warehouse department 
confirm them whether there is any rejection or not.  
19. Compensation or Insurance Claim: If they found there is any rejection then they 
have to go for compensating with the supplier or insurance claim which depends on 
some factors. 
20. Compensation: If they receive complain regarding the quality of the RM then they 
have to arrange the compensation from the suppliers which is related to the following 
steps: 
(i) Firstly they inform the suppliers over the mail regarding the quality issue.  
(ii) If they agreed with them (EK+F) then they fix the amount of compensation 
with proper discussion to their accounts department which considers the whole 
cost including landed cost. 
(iii)  Suppliers usually provide the payments by cheque and then it goes to the 
accounts department with taking proper copies in their file for further 
inspection.  
(iv) In the mean time they have to arrange to send the faulty RM back to the 
suppliers. 
(v) Sometimes the suppliers can arrange to make compensation by adjusting with 
the next consignments.   
(vi) Insurance Claim: if they get company regarding other than the quality issues 
e.g. loss or damage of the materials they should go for the insurance claim 
which considers the following steps: 
(i) Firstly complain have to raise from the QC department 
(ii) Then they usually notify the insurance company over the claim letter 
(iii)  Physical inspection has been made by the third party who is organized 
by the Insurance Company. 
(iv)  They have to provide the necessary documents required by the third 
party. 
(v) In the mean time Insurance Company will arrange to send the 
prejudice letter. 
(vi) They have to share it along with the other documents which are 
required by the insurance company. 
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(vii) Insurance company will arrange to provide Loss on Voucher and they 
have to send it back to the insurance company with proper signing 
from their authorities with retaking a copy in their file. 
(viii) Finally, the cheque is received from the insurance which should share 
it with the accounts as well.   
 
22. C & F bill Processing: This is the final step of import procedure. After receiving the C & 
F bill they have to prepare the bill to submit the accounts department. 
 
23. File Closing: After processing the bill they have to close the file and keep it at record 
room. 
 
3.16 Export Procedure of SK+F pharmaceutical products to abroad. 
  
The export procedure of Pharmaceutical products differs from the export of the other 
products mainly from the regulatory points. The products are to be first registered in the 
respective countries which may take at least two years or more. After successful negotiation 
with the prospective partners in the respective countries and product registration we receive 
the Purchase orders from the importers. We collected export permission from the DGDA and 
ship the goods. Unlike other consumable products Pharmaceutical products needs heavy 
promotions to the prescribers.  
 
Major export destinations are Afghanistan, Myanmar, Sri Lanka, Nepal, Philippines, UAE 
etc. The total exports of pharmaceutical products are shown in Table-:  
 
Table 3.7:  Total Export of Pharmaceutical Products during last five years. 
 
 
Year Export 
( in Million US$) 
Growth Rate 
(%)  
2011 1.0 - 
2012 1.6 60.00 
2013 2.1 31.25 
2014 2.6 23.81 
2015 2.8 7.69 
Source: ES+F, Corporate  Office, Dhaka 
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3.17 Distribution System 
All medicines and medical products of Eskayef are being distributed by Transcom 
Distribution Company Limited (TDCL) which is also a sister concern of Transcom group. 
TDCL has the largest independent distribution setup in Bangladesh with full infrastructural 
facilities provided by a countrywide network of 30 branch offices along with one main office, 
warehouses and delivery vans, directly servicing over 8000 outlets throughout the whole 
country. TDCL is an allied business company of TRANSCOM Groups responsible for 
distributing multi-dimensional products across the country. 
The company started its business with the distribution of quality pharmaceutical products 
manufactured by ESKAYEF, NOVO NORDISK, SERVIER, ALLERGAN  
And consumer brands like Frito Lay, Heinz, Wrigley, Mars, Energizer, Schick, L'Oreal, 
Garnier, ConAgra Foods, McVities and Hemas. It started its diagnostic distribution division 
in 1993 by distributing laboratory equipments and reagents from Hettich(Germany), TREK 
Diagnostics(USA) and Fortress(UK). It also distributes crude oil and oil products from Vitol. 
Basically TDCL has twenty six distribution divisions.   
 
Table 3.8: Main Distribution Centers of TDCL 
 
Division Distribution Centers 
 
Dhaka Dhaka South, Dhaka North, Narayangonj, Savar, 
Keraniganj, Bhairab, Kishoreganj, Tangail, Gazipur, 
Faridpur 
Chittagong Chittagong South, Chittagong North, Camilla, 
Noakhali, Chandpur, Cox’s Bazar, Feni 
Khulna Khulna, Jessore, Kushtia 
Rajshahi Rajshahi, Pabna, Bogra 
Sylhet Sylhet, Moulovi Bazar 
Barisal Barisal, Patuakhali 
Rangpur Rangpur, Dinajpur 
Mymensingh Mymensingh 
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3.17.1 Sales Department of Eskayef Bangladesh Ltd 
 
The sales department of EK+F has been functioning with the key personnel which is shown 
in the Table 3.9:  
 
Table 3.9: Personnel of Sales Department 
 
Position Reporting Officer Number of 
Persons 
 
Director (Sales) Managing Director 1 
Zonal Head Director (Sales) 6 
Regional Head Zonal Head 36 
Field Manager/ Area Manager Regional Head 282 
Medical Services Officer Field Manager/ Area 
Manager 
2022 
  
 Job Description of a Field Manager 
 
The main job responsibility of an area manager is to guide the fellows by following Sales 
Management guide-line to achieve the sales Target, taking market share & ensure product 
mix sales from assigned territory within companies sales policy.             
The key responsibilities include:  
OPERATIONAL 
¾ Achieve Team sales target through Prescription generation. 
¾ Ensure implementation of marketing & sales strategies provided by H.O. / Respective 
Department. 
¾ Cross check up to grass root level- the activities of Team members in order to ensure 
optimum utilization of Company resources. 
¾ Keep up to date information & convey it to H.O about each & every territory within 
the region & review action plan / strategies in response to changing market 
environment. 
¾ Prepare & submit Daily call reports, feedback & market reports to the concerned 
person / Department in time (following day). 
¾ Keep good relation with all the customers & commendable relation with “A” 
potential customers (Sp. Doctors) throughout the assigned territory. 
¾ Keep very good rapport with the key persons of different organizations- (BMA, 
BPMPA, BCDS etc) in the territory. Disseminates related information in time to next 
level superior, so that appropriate measures can be taken. 
¾ Keep all information of the competitor’s activities, especially Sales & marketing 
strategies.  
¾ Ensure effective time management & result oriented call by all Team members. 
¾ Penetrate 100% of your territory to know all out of the market situation & effective 
product positioning by your Team members.   
  
PEOPLE MANAGEMENT  
1. Maintain the team administration by motivating & guiding towards the territory & the 
organizational goal.  
2. Keep everybody in touch with the TECHNIQUE given by the marketing Depertment.  
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3. Keep very good & professional liaison with PMD to understand the Marketing 
Strategies.  
4.  Keep your team members at their best state of knowledge & skill.  
5. Judge the motivation level of team members & make all efforts to keep the same at 
the desire level through regular coaching & counseling session.  
6. Perform annual appraisal of team members & submit in time.  
7. Observe, identify & analyze the training need of team members & subsequently train 
them on the job or recommend for training.  
  
The job challenge of area manager is to achieve target monthly and annually by each team 
members 
JOB DESCRIPTION & JOB SPECIFICATION FOR MSO 
 
The objective of MSO is to promote Eskayef products to the Doctors to increase the 
prescription & sale to achieve the target 
Job Summary is to ensure quality services to the doctors and chemists for building 
professional relationship with them, which will increase Companies image. 
Job Duties vs responsibilities  and accountability: 
DAILY:  
 Visit different institutions & GP areas as per tour program approved by the Field 
Manager. 
 Visit doctors with selected products as per promotional plan and TECHNIQUE to 
generate prescriptions. 
 Visit Chemist to secure order from them to ensure product availability so that no 
prescription is being dishonored. 
 Check Doctors prescription habit, Chemist shelves to identify the products movement. 
 Go through the TECHNIQUE everyday to gather knowledge to ensure productive call 
to the Doctor. 
 Should write daily call report & send it to Head office, copy to Field Manager. 
 Keep record of all promotional material (sample &gift) in DCR regularly. 
 Arrange clinical meeting to increase companies image & establish product image. 
 Follow all the instructions and suggestions from Head Office or FM / RSM. 
 Keep good relationship with BMA, BCDS & TDCL. 
 Keep all official documents (Technique, Circular, official letter etc) confidential. 
 Keep very good professional relation with Product Management Department & feel 
free to contact them for any product related information. 
 Keep up to date the territory information sheet along with all Doctors list. 
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 Top 20 Doctor should be visited regularly. 
 Maintain all official decorum & administration.  
WEEKLY 
Monitor sales achievement sheet to evaluate product wise sales performance & find out the 
facts of achieving or failure with selected products. Discuss with FM / RSM or head office 
for any official assistance you need. Give market feedback, like competitors activities, sales 
strategies, promotional activities etc in regular basis. 
MONTHLY  
 Participate in the monthly Pre Cycle Briefing Session. 
 Prepare monthly tour program on the basis of Standard tour program considering 
complete coverage of different institutions & markets as per potentiality. 
 Give monthly report with expense bill to FM. 
JOB DESCRIPTION & JOB SPECIFICATION  
SELF DEVELOPMENT 
 Read and memorize the TECHNIQUE & all literatures pads given by PMD. 
 Should go through the exams in every month by PMD during PCBS. 
 Should be able to detail the literatures, pads or any detail tips given by PMD 
effectively. 
 Feel free to discuss with FM / RSM or head office- whenever you require for further 
clarification of any points of literatures, pads are not clear to you. 
 Should attend all training programs organized by local officials or Head Office. 
 Should not keep any contact by any means with any political parties. 
MARKET DEVELOPMENT 
 Build-up the company & product image among Medical professionals, Chemists as 
well as to any customers. 
 Maintain good relation with Chemists in order to get better share of OTC items. 
 Maintain Professional relationship with all Medical professionals & Chemists. 
 Visit and maintain a good professional relationship with the members of different 
professional bodies like, BMA, DAB, BCDS, etc 
 Always try to find out new business opportunities, market etc to increase the sales. 
 Special Responsibility is to carryout any other responsibilities assigned by the top 
management time to time. 
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Chapter Four: Analysis of Data and Discussion of Findings 
 
4.0 Introduction 
Primary data has been collected through field survey with respect to the research objectives 
of the study. This includes an examination of the perception of customers (retailers), 
onsumers, executives of the supply chain of management of Eskayef Bangladesh Limited , an 
assessment of the availability and affordability of good quality and efficacious 
pharmaceutical products, an evaluation of the challenges and constraints affecting the 
distribution process and adherence to supply chain management best practices for effective 
and efficient health care delivery. 
 
4.1 Analysis of Data of the Retailers ( Pharmacy Level) 
Total sample size for retailer respondents is 60 equally drawn fifteen from each four major 
cities in Bangladesh. The distribution of respondents from the retail sector has been shown in 
Table: 4.1:   
Table 4.1: Distribution of Respondents (Retailers) 
 
  
Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid Dhaka 15 25.0 25.0 25.0 
  Chittagong 15 25.0 25.0 50.0 
  Khulna 15 25.0 25.0 75.0 
  Rajshahi 15 25.0 25.0 100.0 
  Total 60 100.0 100.0  
 
Source: SPSS Output of Field Survey, January 2016 
 
The reliability statistics of the sample is shown by Cronbach’s alpha which is 0.93.  
.  
Table 4.2: Reliability Statistics 
 
Cronbach's 
Alpha 
Cronbach's 
Alpha Based on 
Standardized 
Items 
N of Items 
.903 .909 15 
 
 Source: SPSS Output of Field Survey, January 2016 
 
The mean  variance, co- variances and item-wise correlations are shown in Table 4.3:    
 
Table 4.3: Summary Item Statistics 
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 Mean Minimum Maximum Range Maximum 
/ 
Minimum 
Variance N of 
Items
Item Means 3.664 3.267 4.150 .883 1.270 .059 15 
Item Variances .912 .541 1.690 1.149 3.123 .076 15 
Inter-Item 
Covariances .349 -.090 .662 .753 -7.328 .027 15 
Inter-Item 
Correlations .401 -.103 .806 .909 -7.846 .036 15 
Source: SPSS Output of Field Survey, January 2016 
 
The Anova with Tukey’s Test for Non-additivity has been shown in the Table-4.3 and Table 
4.5. The F-statistic is significant at 5% level. The Hotelling ‘s T-Squared Test is found 
significant at 5% level.   
  
Table-4.4: ANOVA with Tukey's Test for Nonadditivity 
 
  
Sum of 
Squares df 
Mean 
Square F Sig 
Between People 341.996 59 5.797    
Within 
People 
Between Items 49.929(a) 14 3.566 81.49 .000
  Residual Nonadditivity .695(b) 1 .695 1.236 .267
    Balance 464.042 825 .562    
    Total 464.738 826 .563    
  Total 514.667 840 .613    
Total 856.662 899 .953    
Grand Mean = 3.66, Source: Source: SPSS Output of Field Survey, January 2016 
a  Kendall's coefficient of concordance W = .058. 
b  Tukey's estimate of power to which observations must be raised to achieve additivity = 
1.701. 
 
Table-4.5: Hotelling's T-Squared Test 
 
Hotelling's 
T-Squared F df1 df2 Sig 
79.365 4.420 14 46 .000 
  
 Source: SPSS Output of Field Survey, January 2016 
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Table-4.6: Intra-class Correlation Coefficients 
 
  
Intraclass 
Correlation(a) 
95% Confidence 
Interval 
F Test with True Value 0 
  
Lower Bound Upper Bound Value df1 df2 Sig Lower 
Bound
Single 
Measures .383(b) .296 .491 10.302 59.0 826 .000 
Average 
Measures .903(c) .863 .935 10.302 59.0 826 .000 
Two-way mixed effects model where people effects are random and measures effects are 
fixed. 
a  Type C intraclass correlation coefficients using a consistency definition-the between-
measure variance is excluded from the denominator variance. 
b  The estimator is the same, whether the interaction effect is present or not. 
c  This estimate is computed assuming the interaction effect is absent, because it is not 
estimable otherwise. 
Source: SPSS Output of Field Survey, January 2016 
 
4.2 Retailers’ Knowledge about Supply Chain Management 
Retail Respondents’ knowledge about SCM of EK+F is shown in the following Table 4.7. It 
is observed that 23.3% respondents have reported that they know the SCM very well 
followed by moderate knowledge (21.7%), sufficient knowledge (20%), somehow knowledge 
(20%) and 15% respondents have poor knowledge about SCM.   
  
Table-4.7: Respondent’s Knowledge about SCM 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid poor 9 15.0 15.0 15.0 
  Somehow 12 20.0 20.0 35.0 
  Moderate 13 21.7 21.7 56.7 
  Very Well 14 23.3 23.3 80.0 
  Sufficient 12 20.0 20.0 100.0 
  Total 60 100.0 100.0  
Source: SPSS Output of Field Survey, January 2016 
 
4.2.1 Respondents’ View about SCM. 
The results show that only 25% respondents reported that they identified SCM as Data 
Collection, Supplier, Purchasing, Warehousing, Stocktaking, Distribution. While 46.7% 
respondents viewed SCM as Supplier Selection, Purchasing, Warehousing, Stocking, 
Distribution, 12% viewed SCM as warehousing and distribution and only 6% considered 
SCM as distribution.  
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Table 4.8: Respondent’s View about SCM. 
A. Data Collection, Supplier, Purchasing, Warehousing, Stocktaking, Distribution 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid yes 15 25.0 100.0 100.0 
Missing System 45 75.0   
Total 60 100.0    
 
 
 
B. Supplier Selection, Purchasing, Warehousing, Stocking, Distribution 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid yes 28 46.7 100.0 100.0 
Missing System 32 53.3   
Total 60 100.0   
 
 C. Warehousing, Distribution 
 
 
Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid yes 12 20.0 100.0 100.0 
Missing System 48 80.0    
Total 60 100.0    
 
 D. Distribution 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid yes 6 10.0 100.0 100.0 
Missing System 54 90.0   
Total 60 100.0   
 
Source: SPSS Output of Field Survey, January 2016 
 
4.3 Benefits of SCM 
Multiple Response Analysis (MRA) is carried out to identify the benefits of SCM. Only 2.8% 
respondents identified no impact of SCM, 38.1% respondents reported high impact of SCM, 
31% viewed medium impact. In regards to heavy impact 20.7% respondents opined that SCM 
has heavy impact on the supply chain.   The results are shown in Table 4.9: 
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Table 4.9: Impacts of the Benefits of SCM (Retailers) 
 
Benefits(a) Responses Percent of Cases 
N Percent N 
No Impact 
Moderate Impact 
Medium Impact 
High Impact 
Heavy Impact 
25 2.8% 41.7% 
67 7.4% 111.7% 
279 31.0% 465.0% 
343 38.1% 571.7% 
186 20.7% 310.0% 
 
Total 
 
900 
 
100.0% 
 
1500.0% 
a  Group 
Source: SPSS Output of Field Survey, January 2016 
 
Factor Analysis of the responses regarding the benefits of SCM reveals that shorter lead time 
has high mean (4.15) followed by reduced cycle time (3.97), Reduced waste (3.80), 
competitive advantage (3.83), reduced cost (3.78), greater supply chain visibility (3.72), 
reduced inventory (3.62) etc. The results are shown in Table 4.10. 
 
Table 4.10: Descriptive Statistics of the Indicators of SCM Benefits 
 
Indicators Mean Std. Deviation Analysis N 
Superior Customer Value 3.27 1.300 60 
Reduced Cost 3.78 .825 60 
Cooperative Organizational 
Relationships 3.58 1.046 60 
Effective Business Process 3.47 .929 60 
Information Sharing 3.68 .965 60 
Integrated Relationships 3.78 .958 60 
Shorter Lead Time 4.15 .799 60 
Reduced Waste 3.80 .755 60 
Reduced Cycle Time 3.97 .736 60 
Improve Responsiveness to Customer 
Requirements 3.63 1.025 60 
Greater Supply Chain Visibility 3.72 .993 60 
Enhanced Quality and Service 3.42 .979 60 
Competitive Advantage 3.83 .905 60 
Improved Supply Chain 
Communications 3.27 .972 60 
Reduced Inventory 3.62 .993 60 
Source: SPSS Output of Field Survey, January 2016 
 
KMO and Bartlett’s Test is used to measure sampling adequacy of influencing factors to 
examine the appropriateness of factor analysis. Here the KMO value is 0.768 reveals that the 
sampling adequacy of factor analysis.  The Bartlett’s test of Sphericity (Table 4.11)  indicates 
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that Chi-Square value i.e. 632.94 with 105 degree of freedom meaning that overall significant 
of the analysis.  
 
Table 4.11: KMO and Bartlett's Test 
 
Kaiser-Meyer-Olkin Measure of Sampling 
Adequacy. .768 
Bartlett's Test of 
Sphericity 
Approx. Chi-Square 632.935 
 df 105 
 Sig. .000 
Source: SPSS Output of Field Survey, January 2016 
  
4.3.1 The Communalities of the Factors 
 
Extraction Method: Principal Component Analysis is used find the importance of the factors. 
Here shorter lead time (0.857), reduced cycle time (0.838), reduced waste (0.825), improved 
supply chain communications (0.790), integrated relationship (.0.762), information sharing 
(0.691) are the most important factors for the benefits of SCM.  The results are shown in 
Table 4.12: 
Table 4.12: The Communalities of the Factors 
 
Indicators Initial Extraction 
 
Superior Customer Value 1.000 .282 
Reduced Cost 1.000 .724 
Cooperative Organizational Relationships 1.000 .602 
Effective Business Process 1.000 .713 
Information Sharing 1.000 .691 
Integrated Relationships 1.000 .762 
Shorter Lead Time 1.000 .857 
Reduced Waste 1.000 .825 
Reduced Cycle Time 1.000 .838 
Improve Responsiveness to Customer Requirements 1.000 .649 
Greater Supply Chain Visibility 1.000 .761 
Enhanced Quality and Service 1.000 .709 
Competitive Advantage 1.000 .745 
Improved Supply Chain Communications 1.000 .790 
Reduced Inventory 1.000 .548 
Extraction Method: Principal Component Analysis. 
The extraction sums of squared loadings that component 1 has 45.05% variance, component 
2 has 17.65% and component 3 has 7.23% variance. . 
Source: SPSS Output of Field Survey, January 2016 
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The total variance explained of the factor analysis is shown in Table 4.13. The initial 
eigenvalues for components 1, 2 and 3 are respectively 6.758, 2.65 and 1.09. It reveals that 
the component 1 has alone explained 45.07% of variance while component 2 has explained 
17.66%, Component 3 has explained 7.27%. Other components are insignificant in terms of 
explaining total variance of the model.  The rotation sums of squared loadings for component 
1 is 4.82 (32.16%), 3.49 (23.28%) for component 2 and 2.18 (14.55%) for component 3. 
Table 4.13: Total Variance Explained 
 
C
om
po
ne
nt
   
Initial Eigenvalues Extraction Sums of Squared Loadings 
Rotation Sums of Squared 
Loadings 
Total % of 
Variance 
Cumulative  
% 
Total % of 
Variance 
Cumulative 
 % 
Total % of 
Variance 
Cumulative 
 % 
1 6.75
8 45.057 45.057 
6.75
8 45.057 45.057 
4.82
4 32.159 32.159 
2 2.64
8 17.656 62.713 
2.64
8 17.656 62.713 
3.49
1 23.276 55.435 
3 1.09
1 7.273 69.986 
1.09
1 7.273 69.986 
2.18
3 14.551 69.986 
4 .838 5.587 75.573       
5 .657 4.383 79.956       
6 .628 4.185 84.141       
7 .560 3.731 87.872       
8 .401 2.672 90.545       
9 .344 2.295 92.840       
10 .318 2.121 94.962       
11 .251 1.673 96.635       
12 .207 1.383 98.017       
13 .148 .984 99.001       
14 .093 .618 99.619         
15 .057 .381 100.000         
Extraction Method: Principal Component Analysis. 
Source: SPSS Output of Field Survey, January 2016 
 
 
 
 
 
 
 
 
 
 
 
 
61 | P a g e  
 
The Scree Plot for Principal Component Analysis is shown in Figure 4.1:  
Figure 4.1: Scree Plot for Principal Component Analysis 
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4.3.2 Component Matrix Analysis   
The weight of each factor in each component is shown in Table 4.14:  
 Table 4.14: Component Matrix(a) 
 
Indicators 
  
Component 
1 2 3 
Superior Customer Value .492 -.148 .135 
Reduced Cost .737 -.404 .137 
Cooperative Organizational Relationships .650 -.300 .300 
Effective Business Process .738 -.398 .104 
Information Sharing .698 -.430 .139 
Integrated Relationships .733 .474 .003 
Shorter Lead Time .646 .250 -.614 
Reduced Waste .753 .492 .125 
Reduced Cycle Time .727 .383 -.404 
Improve Responsiveness to Customer 
Requirements .680 .430 -.031 
Greater Supply Chain Visibility .757 -.349 -.258 
Enhanced Quality and Service .772 -.282 .184 
Competitive Advantage .656 -.519 -.214 
Improved Supply Chain Communications .432 .633 .450 
Reduced Inventory .471 .546 .168 
Extraction Method: Principal Component Analysis. 
a  3 components extracted. 
 
 
From the component matrix it is found that 12 factors have high influence on the benefits of 
SCM. These are enhanced quality and service (0.772), greater supply chain visibility (0.757) 
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reduced waste (0.753), effective business process (0.737), reduced cost (0.737), reduced 
cycle time (0.727), information sharing (0.698), improve responsiveness to customer 
requirements(0.680), competitive advantage (0.656), cooperative organizational relationships 
(0.6.50). Components 2 and 3 are not important as most of the factors have negative 
coefficients.    
 
The rotated weight of each indicator for each component is shown in Table 4.15: 
 
Table 4.15: Rotated Component Matrix(a) 
 
Indicators 
  
Component 
1 2 3 
Superior Customer Value .490 .194 .066 
Reduced Cost .832 .126 .126 
Cooperative Organizational 
Relationships .742 .225 -.038 
Effective Business Process .822 .118 .156 
Information Sharing .821 .087 .102 
Integrated Relationships .248 .738 .394 
Shorter Lead Time .176 .279 .865 
Reduced Waste .280 .811 .298 
Reduced Cycle Time .204 .505 .736 
Improve Responsiveness to Customer 
Requirements .228 .665 .394 
Greater Supply Chain Visibility .719 .022 .494 
Enhanced Quality and Service .793 .256 .120 
Competitive Advantage .761 -.142 .382 
Improved Supply Chain 
Communications .031 .882 -.105 
Reduced Inventory .047 .724 .147 
Method: Principal Component Analysis.  
  Rotation Method: Varimax with Kaiser Normalization. 
a  Rotation converged in 5 iterations. 
 
Table 4.16 shows the component transformation. Here component 1 has more weight as 
compared to component 2 and component 3.  
 
Table 4.16: Component Transformation Matrix 
 
Component 1 2 3 
 
1 .742 .515 .430 
2 -.627 .760 .172 
3 .238 .397 -.887 
Extraction Method: Principal Component Analysis. 
Rotation Method: Varimax with Kaiser Normalization. 
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Figure 4.2: Component Plot in Rotated Space 
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The component score coefficients are shown in Table 4.17: 
 
Table 4.18:  Component Score Coefficient Matrix 
 
 Indicators Component 
  1 2 3 
Superior Customer Value .118 .044 -.088 
Reduced Cost .206 -.010 -.091 
Cooperative Organizational 
Relationships .208 .072 -.222 
Effective Business Process .198 -.020 -.063 
Information Sharing .209 -.020 -.097 
Integrated Relationships -.031 .193 .075 
Shorter Lead Time -.122 -.102 .557 
Reduced Waste -.006 .244 -.021 
Reduced Cycle Time -.099 .018 .399 
Improve Responsiveness to Customer 
Requirements -.034 .164 .097 
Greater Supply Chain Visibility .109 -.136 .235 
Enhanced Quality and Service .192 .045 -.119 
Competitive Advantage .148 -.177 .182 
Improved Supply Chain 
Communications -.004 .378 -.297 
Reduced Inventory -.041 .254 -.071 
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization.  
  Component Scores. 
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Eigenvalues of the three functions and Wilk’s Lambda is shown in Table 4.19.  Function 1 
has higher eigenvalue ( 2.041) and 65.2% variance of function 1 is explained while the 
eigenvalue for function 1 is estimated at 0.719 and 23.0% variance is explained. The 
eigenvalue of function 3 is 0.371 and only 11.80% variance is explained.  
 
Table 4.18: Summary of Canonical Discriminant Functions 
 
A. Eigenvalues 
 
Function Eigenvalue 
% of 
Variance 
Cumulative 
% Canonical Correlation 
1 2.041(a) 65.2 65.2 .819 
2 .719(a) 23.0 88.2 .647 
3 .371(a) 11.8 100.0 .520 
a  First 3 canonical discriminant functions were used in the analysis. 
 
B. Wilks' Lambda 
 
Test of 
Function(s) 
Wilks' 
Lambda Chi-square df Sig. 
1 through 3 .140 97.471 45 .000 
2 through 3 .425 42.411 28 .040 
3 .730 15.609 13 .271 
 
The Chi-square test of function 1 through 3 is significant at 1% level where the p-value is 
.000 and the same for function 2 through is also significant at 5% level. 
 
Table 4.19: Standardized Canonical Discriminant Function Coefficients 
 
  Function 
  1 2 3 
Superior Customer Value .435 .455 .060 
Reduced Cost 1.067 .136 -.584 
Cooperative Organizational Relationships -.953 .084 -.206 
Effective Business Process .294 .418 .935 
Information Sharing -.649 .134 -.262 
Integrated Relationships .069 .619 .035 
Shorter Lead Time .169 -.249 -.419 
Reduced Waste -1.576 -.698 .023 
Reduced Cycle Time .076 -.548 .206 
Improve Responsiveness to Customer 
Requirments .216 .394 -.092 
Greater Supply Chain Visibility .107 -.590 -.023 
Enhanced Quality and Service -.365 .081 .520 
Competitive Advantage 1.017 .397 -.043 
Improved Supply Chain Communications .539 .696 -.668 
Reduced Inventory -.229 .005 .733 
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Table 4.20: Structure Matrix 
 
 Indicators Function 
  1 2 3 
Reduced Waste -.416(*) .311 .061 
Enhanced Quality and Service .048 .499(*) .392 
Improved Supply Chain Communications -.306 .491(*) -.202 
Superior Customer Value .063 .403(*) .134 
Reduced Cost .125 .394(*) .081 
Information Sharing .005 .373(*) .124 
Cooperative Organizational Relationships -.125 .367(*) .016 
Integrated Relationships -.224 .358(*) -.043 
Improve Responsiveness to Customer 
Requirements -.176 .329(*) .155 
Competitive Advantage .231 .233(*) .167 
Shorter Lead Time -.005 -.073(*) -.052 
Effective Business Process .031 .349 .491(*) 
Reduced Inventory -.241 .159 .350(*) 
Greater Supply Chain Visibility .136 .165 .314(*) 
Reduced Cycle Time -.121 -.009 .135(*) 
Pooled within-groups correlations between discriminating variables and standardized 
canonical discriminant functions  
 Variables ordered by absolute size of correlation within function. 
*  Largest absolute correlation between each variable and any discriminant function 
 
Table 4.21: Canonical Discriminant Function Coefficients 
 
 Factors 
  
Function 
1 2 3 
Superior Customer Value .346 .362 .048 
Reduced Cost 1.349 .172 -.738 
Cooperative Organizational Relationships -.943 .083 -.204 
Effective Business Process .335 .475 1.065 
Information Sharing -.689 .143 -.278 
Integrated Relationships .077 .688 .039 
Shorter Lead Time .206 -.304 -.512 
Reduced Waste -2.428 -1.075 .035 
Reduced Cycle Time .102 -.739 .277 
Improve Responsiveness to Customer 
Requirements .220 .401 -.094 
Greater Supply Chain Visibility .110 -.605 -.024 
Enhanced Quality and Service -.404 .090 .577 
Competitive Advantage 1.178 .460 -.050 
Improved Supply Chain Communications .635 .820 -.787 
Reduced Inventory -.245 .005 .782 
(Constant) .663 -2.611 -.162 
 
 
66 | P a g e  
 
Table 4.22: Functions at Group Centroids 
 
Location of Respondents Function 
 1 2 3 
Dhaka .952 .762 -.758 
Chittagong -2.139 -.492 -.287 
Khulna -.254 .820 .824 
Rajshahi 1.441 -1.090 .220 
 
Unstandardized canonical discriminant functions evaluated at group means 
 
Table 4.23: Classification Function Coefficients 
 
  Location of Respondents 
  Dhaka Chittagong Khulna Rajshahi 
Superior Customer 
Value 1.264 -.239 .944 .809 
Reduced Cost 3.126 -1.607 .342 2.744 
Cooperative 
Organizational 
Relationships 
.105 2.819 .924 -.709 
Effective Business 
Process 1.319 .189 2.627 1.643 
Information Sharing .158 1.978 .557 -.715 
Integrated 
Relationships -1.719 -2.802 -1.710 -2.917 
Shorter Lead Time 5.005 4.507 3.928 5.168 
Reduced Waste -2.129 6.739 .792 -1.290 
Reduced Cycle Time -.292 .450 -.019 1.398 
Improve 
Responsiveness to 
Customer 
Requirements 
-.257 -1.484 -.647 -.984 
Greater Supply Chain 
Visibility -3.289 -2.879 -3.494 -2.137 
Enhanced Quality and 
Service -1.387 .020 .017 -1.188 
Competitive 
Advantage 5.801 1.558 4.327 5.475 
Improved Supply 
Chain 
Communications 
5.857 2.498 3.895 3.880 
Reduced Inventory 1.116 2.234 2.648 1.750 
(Constant) -30.043 -30.312 -30.927 -25.669 
Fisher's linear discriminant functions 
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4.4 Regression Analysis 
Table 4.26: Model Summary(b) 
 
Mode
l R 
R 
Square 
Adjus
ted R 
Squar
e 
Std. 
Error of 
the 
Estimate Change Statistics 
Durbin-
Watson 
  
R Square 
Change 
F 
Chang
e df1 df2 
Sig. F 
Change 
R 
Square 
Change 
F 
Cha
nge df1 df2
Sig. F 
Change 
1 .527(a) .278 .053 1.265 .278 1.235 14 45 .285 2.055
a  Predictors: (Constant), Reduced Inventory, Competitive Advantage, Shorter Lead Time, 
Improved Supply Chain Communications, Cooperative Organizational Relationships, 
Effective Business Process, Improve Responsiveness to Customer Requirements, Information 
Sharing, Integrated Relationships, Enhanced Quality and Service, Reduced Cycle Time, 
Reduced Cost, Greater Supply Chain Visibility, Reduced Waste 
b  Dependent Variable: Superior Customer Value 
 
 
 Table: 4.25: ANOVA(b) 
 
Model   
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 27.680 14 1.977 1.235 .285(a) 
  Residual 72.054 45 1.601    
  Total 99.733 59     
a  Predictors: (Constant), Reduced Inventory, Competitive Advantage, Shorter Lead Time, 
Improved Supply Chain Communications, Cooperative Organizational Relationships, 
Effective Business Process, Improve Responsiveness to Customer Requirments, Information 
Sharing, Integrated Relationships, Enhanced Quality and Service, Reduced Cycle Time, 
Reduced Cost, Greater Supply Chain Visibility, Reduced Waste 
b  Dependent Variable: Superior Customer Value 
 
  
4.5 Successfulness of  SCM of SK+F (Retailers) 
 
The successfulness of SCM as reported by retailers is shown in Table 4. 26. About 30.0% 
respondents reported that SCM of SK +F is successful, 25% as very successful, 21.7% as 
successful somewhat. Only 8.3% respondent reported that SCM is not successful at all, 15% 
reported as not successful.  
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Table 4.26: Successfulness of  SCM of SK+F (Retailers) 
 
 Indicators 
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Not Successful At All 5 8.3 8.3 8.3 
  Not Successful 9 15.0 15.0 23.3 
  Successful Somewhat 13 21.7 21.7 45.0 
  Successful 18 30.0 30.0 75.0 
  Very Successful 15 25.0 25.0 100.0 
  Total 60 100.0 100.0  
Source: SPSS Output of Field Survey, January 2016. 
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Regarding view on cost of EK+F products 43.3% retail respondents agreed that the coist is 
high as compared to other companies while 20.0% strongly agreed with high cost while 
36.7% respondent are undecided on this issue. Table 4.22 shows the view on cost:   
Table 4.27: View on Cost (Retailers) 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Strongly 
Agree 12 20.0 20.0 20.0
  Agree 26 43.3 43.3 63.3
  Undecided 22 36.7 36.7 100.0
  Total 60 100.0 100.0   
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4.6 Analysis of Responses of Executives 
Supply chain is the management of a network of retailers, distributors, transporters, storage 
facilities and suppliers that participate in the sale, delivery and production of a particular 
product. The results from the responses of executives indicated that 50% of the respondents 
strongly agreed, 45% agreed and 5% were undecided as to the definition of the supply chain. 
This indicates that the 95% of the respondents are knowledgeable about the subject they 
provided answers for. One hundred percent (100%) of the respondents who were surveyed in 
the wholesale facilities considered data collection, supplier selection, purchasing, 
warehousing, stock taking, distribution as stages in supply chain management. However, the 
retail survey results indicated that 75% of the interviewees considered data collection, 
supplier selection, purchasing, warehousing, stock taking, and distribution as the stages in 
supply chain management 
 
4.6.1 Successfulness of SCM  
Regarding successfulness of SCM, 50% respondents reported it as very successful. 27.7% 
respondents identified SCM as successful, 16.7% reported as successful somewhat and only 
6.7% as not successful.  
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Table 4.23: Successfulness (SK+F Executives) 
 
  
Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid Not Successful 2 6.7 6.7 6.7 
  Successful Somewhat 5 16.7 16.7 23.3 
  Successful 8 26.7 26.7 50.0 
  Very Successful 15 50.0 50.0 100.0 
  Total 30 100.0 100.0  
 
Successfulness
Very SuccessfulSuccessfulSuccessful SomewhatNot Successful
Fr
eq
ue
nc
y
15
10
5
0
Successfulness
 
 
 
4.6.2 Supply Chain Challenges: 
From the responses of 30 officials from SK+F and TDCL the following challenges have been 
identified:  
• Lack of coordination 
• Inventory management 
• Absent demand information 
• Human resource dependency 
• Order management 
• Shortage avoidance 
• Expiration 
• Warehouse management 
• Temperature control 
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• Shipment visibility 
The results of field survey reveals that 86.7% respondents has identified lack of coordination 
as a challenge to SCM while 80% as inventory management, 80% as order management, 
33.3% as absent demand management, 50% as human resource management, 20% as 
shortage avoidance, 53.3% as expiration management, 66.7% as warehouse management, 
63.3% as temperature control and 66.7% as shipment visibility.  
Table 4.29: Frequency Distribution of Challenges 
Challenges Frequency 
Yes Percentage No Percentage 
Lack of Coordination 26 86.7 4 13.3 
Inventory Management 24 80 6 20 
Absent Demand Information 10 33.3 20 66.7 
Human Resource Dependency 15 50 15 50 
Order Management 24 80 6 20 
Shortage Avoidance 6 20 24 80 
Expiration 16 53.3 14 46.7 
Warehouse Management 20 66.7 10 33.3 
Temperature Control 19 63.3 11 36.7 
Shipment Visibility 20 66.7 10 33.3 
Source : Field Survey, 2016 
 
As a group 60% respondents identified supply chain management challenges as yes while 
40% as no.  
Table 4.30: Challenges Frequencies (Group) 
 
  Responses 
Percent of 
Cases 
  N Percent N 
 
SCMCa  
 
Yes 180 60.0% 600.0%
  No 120 40.0% 400.0%
Total 300 100.0% 1000.0%
a  Group 
 
 
4.6.3 Factor Analysis 
 
The factor analysis of the multiple responses have been done excluding three factors such as 
absent demand information, shortage avoidance and expiration because of low correlation 
coefficient. The components have been identified. The results have been shown in Table: 
4.31:.  
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Table 4.31: Component Matrix(a) 
 
  
Component 
1 2 3 
Order Management .671 -.159 -.180
Inventory 
Management -.643 .188 -.355
Temperature 
Control .476 -.456 .211
Shipment Visibility .228 .803 -.146
Human Resource 
Dependency .542 .564 .275
Lack of 
Coordination -.384 .115 .843
Extraction Method: Principal Component Analysis. 
a  3 components extracted. 
 
 
 
 
 Table 4.32: Rotated Component Matrix(a) 
 
  
Component 
1 2 3 
Inventory 
Management -.742 -.154   
Temperature 
Control .668 -.173   
Order Management .528 .143 -.457
Shipment Visibility -.236 .802 -.136
Human Resource 
Dependency .294 .770   
Lack of 
Coordination     .933
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization. 
a  Rotation converged in 5 iterations. 
 
 Table 4.33: Component Transformation Matrix 
 
Component 1 2 3 
1 .793 .448 -.413
2 -.444 .889 .111
3 .417 .095 .904
Extraction Method: Principal Component Analysis.   
 Rotation Method: Varimax with Kaiser Normalization. 
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4.7 Quality, Availability and Affordability of SK+F Products (Retailers and Executives) 
 
SK+F produces high quality products. The retailers survey results show that 36.7% of the 
respondents rated products from EK+F as better, 31.7% as good, 18.3% as excellent as shown 
in Table:  . Regarding availability of EK+F products the survey results show that 33.3% rated 
as good, 31.7% as better and 21.7% as excellent. With regards to affordability 36.7 % 
respondents rated EK+F as good, 28.3% as excellent, 26.7% as better and 8.3% as moderate.  
 
Table 4.34 : Quality, Availability and Affordability 
A. Quality 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid Excellent 11 18.3 18.3 18.3 
  Better 22 36.7 36.7 55.0 
  Good 19 31.7 31.7 86.7 
  Moderate 8 13.3 13.3 100.0 
  Total 60 100.0 100.0  
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B. Availability 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid Excellent 13 21.7 21.7 21.7 
 Better 19 31.7 31.7 53.3 
 Good 20 33.3 33.3 86.7 
 Moderate 8 13.3 13.3 100.0 
 Total 60 100.0 100.0  
 
C. Affordability 
 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Valid Excellent 17 28.3 28.3 28.3 
  Better 16 26.7 26.7 55.0 
  Good 22 36.7 36.7 91.7 
  Moderate 5 8.3 8.3 100.0 
  Total 60 100.0 100.0  
 
4.3 Customer View on SCM of SK+F 
Customer perception about SCM of EK+ F reveals that 46.7% respondents did not know it, 
33.3% as know somehow and 20% know well.  
Table 4.35: Customer Perception on SCM 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Know Well 6 20.0 20.0 20.0 
  Know 
Somehow 10 33.3 33.3 53.3 
  Do not know 14 46.7 46.7 100.0 
  Total 30 100.0 100.0   
 
 
Regarding quality of SK+F products 43.3% respondents rated as better, 36.7% as good, 
13.3% as moderate and 6.7% as moderate.  
 Table 4.36: Quality 
 
 Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Excellent 2 6.7 6.7 6.7 
 Better 13 43.3 43.3 50.0 
 Good 11 36.7 36.7 86.7 
 Moderate 4 13.3 13.3 100.0 
 Total 30 100.0 100.0  
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Regarding availability of products 36.7% respondents rated EK+F as better, 26.7% as good, 
16.7 % as moderate,  6.7% as excellent and 13.3% as poor.  
 
 Table 4.37: Availability 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Excellen
t 2 6.7 6.7 6.7
Better 11 36.7 36.7 43.3
Good 8 26.7 26.7 70.0
Moderat
e 5 16.7 16.7 86.7
Poor 4 13.3 13.3 100.0
Total 30 100.0 100.0  
 
 
Regarding affordability of products 36.7% respondents rated EK+F as good, 307% as 
moderate, 23.3 % as better,  6.7% as poor and 3.3% as excellent.  
 Table 4.38: Affordability 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Excellen
t 1 3.3 3.3 3.3
Better 7 23.3 23.3 26.7
Good 11 36.7 36.7 63.3
Moderat
e 9 30.0 30.0 93.3
Poor 2 6.7 6.7 100.0
Total 30 100.0 100.0  
 
Regarding frequency of use of products 46.7% respondents reported more frequently use 
while 53.3 mentioned occasionally use.  
 
 Table 4.39: Frequency of Use 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid More 
Frequently 14 46.7 46.7 46.7 
Occasionally 16 53.3 53.3 100.0 
Total 30 100.0 100.0   
 
 
Regarding rating of products 33.3% respondents rated SK+F as good, 26.7% as good, 23.3 % 
as moderate,  16.7% as excellent.  
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 Table 4.40: Rating of Products 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
Valid Excellent 5 16.7 16.7 16.7 
 Better 8 26.7 26.7 43.3 
 Good 10 33.3 33.3 76.7 
 Moderate 7 23.3 23.3 100.0 
 Total 30 100.0 100.0  
 
  
 
Regarding perception SCM 46.7 respondents reported do not know, 33.3% as somehow know 
and 20% as know well.   
 
4.9 Risks in Pharmaceutical Supply Chain 
Access to medicine as a human right is one of the main objectives of healthcare systems. 
Pharmaceutical supply chain should provide medicines in the right quantity, with the 
acceptable quality, to the right place and customers, at the right time and with optimum cost 
to be consistent with health system’s objectives and also it should make benefits for its 
stockholders (Kaufmann et al.). Any risks affecting the pharmaceutical supply chain, not only 
can waste the resources but also can threaten the patients’ life by hindering access to 
medicines. Risk management is not only important in the pharmaceutical supply chain, but 
also is a major player in other aspects of pharmaceuticals such as prescription and uses of 
medicine (Schneider et al. (2008). Assessing and implementing the strategies to manage the 
risks in pharmaceutical supply chain is essential in health systems. The importance of the risk 
management is becoming more vital because medicine is a highly regulated product which is 
under the controls and tight limitations of public regulatory authorities( Craighead et al, 2006, 
Koh et al, 2003). Also supply of medicines as strategic goods in developing countries with 
much economic, social and political instability is faced with more uncertainties and 
vulnerabilities ( Enyinda et al., 2010). 
 
Supply chain risk management (SCRM) is a crucial and indivisible part of supply chain 
managements to achieve mentioned objectives.  SCRM attempts to minimize supply chain 
vulnerability and uncertainties through mitigation plans(Breen, L 2008, Vanany, 2010) 
Therefore it is essential to identify, assess and prioritize all risks to reduce and control the 
probability and impacts of unfortunate events. It is aimed to managing the risks in a complex 
and dynamic supply and demand networks. 
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Various works have been reported regarding different aspects of supply chain risks and risks 
management in the manufacturing sectors. In pharmaceutical sector, although there are some 
review studies in supply chain risk management with focus on counterfeit, supply chain 
logistics, quality assurance and enterprise risk management but there is not any systematic 
review on the pharmaceutical risk management with perspective of manufacturers’ risks; 
meanwhile, there are some systematic reviews on SCRM in other industries. 
4.9.1 Risk Responses of Retailers 
About 65% of the retailer respondents reported supply and supplier risks, 41.7% as 
organization and strategies risks, 68.3% as financial risks, 75% as logistic risks, 38.3% as 
market issues, 68.33% as regulatory risks, 61.7% as inventory risks, 56.7% counterfeit risks. 
The results are shown in Table 4.20: Supply Chain Risks (Retails)-   
Table 4.41: Supply Chain Risks (Retails)  
 
Sl Risks Yes No 
  Frequency Percent Freq Percent
1 Supply and Supplier Risks 39 65 21 35 
2 Organization & Strategic Risks 25 41.7 35 58.3 
3 Financial Risks 41 68.3 19 31.7 
4 Logistic Risks 45 75 15 25 
5 Market Issues 23 38.3 37 61.7 
6 Regulatory Risks 41 68.3 19 31.7 
7 Inventory Risks 37 61.7 23 38.3 
8 Counterfeit Risks  34 56.7 26 43.3 
  
 
From the above analysis it is evident that logistic risks is the most important risks followed 
by regulatory risks, financial risks, supply and supplier risks, inventory risks, counterfeit 
risks, organization and strategies risks and market issues.    
4.9.2 Risk Responses of Executives 
About 80% of the executive respondents reported supply and supplier risks, 26.7% as 
organization and strategies risks, 90% as financial risks, 86.7% as logistic risks, 63.3% as 
market issues, 86.7% as regulatory risks, 90% as inventory risks, 76.7% as counterfeit risks. 
The results are shown in Table 4.42: 
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Table 4.42: Supply Chain Risks (Executives)  
 
Sl Risks Yes No 
  Frequency Percent Freq Percent
1 Supply and Supplier Risks 39 65 21 35 
2 Organization & Strategic Risks 25 41.7 35 58.3 
3 Financial Risks 41 68.3 19 31.7 
4 Logistic Risks 45 75 15 25 
5 Market Issues 23 38.3 37 61.7 
6 Regulatory Risks 41 68.3 19 31.7 
7 Inventory Risks 37 61.7 23 38.3 
8 Counterfeit Risks  34 56.7 26 43.3 
   
A. Supply & Supplier Risks 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 6 20.0 20.0 20.0
Yes 24 80.0 80.0 100.0
Total 30 100.0 100.0  
 
B. Organisation & Strategies Risk 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 22 73.3 73.3 73.3
Yes 8 26.7 26.7 100.0
Total 30 100.0 100.0  
 
C. Financial Risk 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 3 10.0 10.0 10.0
  Yes 27 90.0 90.0 100.0
  Total 30 100.0 100.0  
 
D. Logistic Risk 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 4 13.3 13.3 13.3
  Yes 26 86.7 86.7 100.0
  Total 30 100.0 100.0  
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E. Market Issues 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 11 36.7 36.7 36.7
  Yes 19 63.3 63.3 100.0
  Total 30 100.0 100.0  
 
  
F. Regulatory Risks 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 4 13.3 13.3 13.3
Yes 26 86.7 86.7 100.0
Total 30 100.0 100.0  
 
G. Inventory Risks 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 3 10.0 10.0 10.0
Yes 27 90.0 90.0 100.0
Total 30 100.0 100.0  
 
H, Counterfeit Risks 
 
  
Frequenc
y Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid No 7 23.3 23.3 23.3
Yes 23 76.7 76.7 100.0
Total 30 100.0 100.0  
 
It is found that financial and inventory risks are the most important risks followed by logistic 
risks, regulatory risks, counterfeit risks, market issues and organization and strategies risks.  
 
4.10 Recommendation for Effective and Efficient Supply Chain (Retailers)  
 
The most important recommendation form the retail responses is provide more affordable 
drugs (26.7%). Customer relationship management is also found as an important 
recommendation ( 20%). The other recommendations are decentralized distribution system 
(16.7%), improve data and communication system (13.3%, competitive price( 8.3%), provide 
more logistics(6.7%), strengthen management structure( 5%) and open wholesale and retail 
branches(3.3%).  
 
Table 4.43: Recommendation for Effective and Efficient Supply Chain(Retilers) 
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 Responses Percent of Cases 
  N Percent  
RES(a) Open Wholesale and Retail Branches 2 3.3% 3.4% 
 Provide More Affordable Drugs 16 26.7% 27.1% 
 Strengthen Management Structure 3 5.0% 5.1% 
 Improve Data and Communication 
System 8 13.3% 13.6% 
 Competitive Price 5 8.3% 8.5% 
 Provide More Logistics 4 6.7% 6.8% 
 Customer Relationship Management 12 20.0% 20.3% 
 Decentralized Distribution System 10 16.7% 16.9% 
Total 60 100.0% 101.7% 
a  Dichotomy group tabulated at value 1. 
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Chapter Five: Recommendations and Conclusion 
5.1 Recommendations 
From the analysis of the results obtained from the surveys, the following recommendations 
have been made to enable ‘Eskayef Bangladesh Limited’ to achieve its main vision is to lead 
the national pharmaceutical market, to be recognized as a multinational conglomerate from 
Bangladesh and stand out as a model of efficiency & trust to our collaborators, consumers, 
health care professionals & society. These include:  
 
1. ‘Eskayef Bangladesh Limited’ should employ more marketing staff in order to 
effectively distribute its products to a wider customer base.  
 
2. ‘Eskayef Bangladesh Limited’ should continue to produce the high quality 
pharmaceuticals products but at a less production cost so the prices of its products 
would be cheaper to ensure that low level income earners could also patronize them 
since the poor in Bangladesh form a larger proportion of the population.  
 
3. To help the distribution chain, ‘Eskayef Bangladesh Limited’ should occasionally 
organize education seminars for communities to help them know the usage of drugs 
and the possible adverse effects of their abuse. It is well known in Bangladesh, that 
not all sick people go to the hospital or ask their pharmacists for correct medication, 
they rather purchase medicines from drug peddlers and unapproved retailers.  
 
4. ‘Eskayef Bangladesh Limited’ should improve on its data collection and 
communication systems. These would enhance information flow within the Company 
and promote the implementation of new strategies and directives. It would also help to 
reduce its bad debts since customers can be followed up effectively to pay whatever 
they purchase. Good data collection system would help it improve on its forecasting 
system to reduce the shortages it encounters in order to effectively meet the needs of 
its customers.  
 
5. ‘Eskayef Bangladesh Limited’ should buy more distribution vans to improve its 
supply chain system.  
 
6. The Government of Bangladesh should encourage the development of local 
pharmaceutical manufacturing capacity by reducing or wavering off some of the taxes 
on pharmaceutical raw materials also called active pharmaceutical ingredients (APIs). 
In addition, the government should encourage the expansion of the local 
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pharmaceutical companies by giving tax reliefs to companies with branches or offices 
in most if not all regional capitals and district capitals of the country.  
 
7. Government should discourage foreign pharmaceutical companies from considering 
and/or taking Bangladesh as a dumping site for the substandard or disapproved 
products by other national food and drugs authorities. 
 
8. Medicine export should be emphasized to LDCs than any other countries: Some 
companies are aggressive to enter the highly regulated overseas markets, such as, 
USA, Australia, Europe, Canada, France, and Golf countries. But the practical 
observation is that getting export status to those countries requires huge investment in 
the manufacturing plant to achieve certification from different international drug 
regulatory authorities, highly sophisticated documentation, and huge initial capital 
investment. Actually the export volume to the highly regulated countries will not be 
easily feasible; rather we can perform pretty well and can potentially increase our 
export if the exporters become more attentive to LDCs. Among 50 LDCs, only 
Bangladesh has its strong fundamental and modern manufacturing base, hence we can 
easily share the drug market of rest of the LDCs. So, considering the practical 
situation, the LDCs should be the targeted markets of our pharmaceuticals, of course, 
side by side, moderately regulated and highly regulated markets may be explored 
gradually. However, we can establish joint-venture, tool manufacturing, and contract- 
manufacturing business with the companies of developed countries, not only for 
exporting medicines. 
 
9. Establishing Export cell by the govt./private Consultancy firms may promote 
Pharma export: Government can establish specialized Export Cell to promote 
exports of pharmaceuticals to grab and capitalize the huge export opportunities in 
LDCs. Some private Consultancy firms having experience and expertise in drug 
export professionally can be engaged to assist the pharmaceutical companies who do 
not have the technical and expertise know-how to go through the entire process of 
export, or have lacking in documentation skills or even do not have the skilled man 
power to deal with the drug export. Thus, Consultancy firms can play a significant 
role to explore export to maximum countries, accelerate export activities, and to 
reduce the overall cost of export. Even some small companies having International 
Marketing Department (IMD) can explore the benefits of outsourcing by hiring 
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Export Consultants to reduce its overhead expenditure and make a comparative study 
of cost-benefit ration to justify having IMD. 
 
5.2 Conclusions  
 
The pharmaceutical sector has already been declared as the thrust sector by the government 
of Bangladesh. Bangladesh has built a strong baseline and going towards the self-sufficiency 
for the production of medicine. Meanwhile, some companies have started to produce vaccine, 
insulin, anticancer drugs, etc. Our pharmaceutical industries are successful in domestic 
market. Now, it’s the time to grow our international market because we passing golden time 
getting the opportunity of patent exemption by the TRIPS until 2030. Besides the above 
discussing points, providing cash incentive by the govt. to the medicine exporters, like RMG 
may encourage pharmaceutical exporters. International fair arrangement by Export Promotion 
Bureau (EPB) is a very effective way to search buyers and to establish business in a new 
country. A lot of initiative have been taken by BAPI in different times, such as, high level 
pharmaceuticals delegation team visited foreign countries to explore export initiated by 
BAPI. This organization also upheld the demand and urged to the government and other 
concerning authorities for API Park, Bioequivalence test laboratory, Central drug testing 
laboratory, cash incentives, problems in remit transfer and sample sending etc. But many 
issues are yet to resolve. We have already wasted our valuable time and still losing to build 
our infrastructure for export. The government should really be attentive to remove all the 
obstacles and solve all the problems to see pharmaceutical sector as a vital player in 
international market.  
 
From the study it can be concluded that ‘Eskayef Bangladesh Limited’ has an effective 
supply chain management strategy even though there is still room for improvement. ‘Eskayef 
Bangladesh Limited’ provides good quality and efficacious medicines that are affordable and 
available to all level of income earners in Bangladesh. ‘Eskayef Bangladesh Limited’ does 
this by importing both patented and generic medicines from the world’s leading 
pharmaceutical companies so nationals from all over the world in Bangladesh can have their 
trusted brands of medicines. Again, ‘Eskayef Bangladesh Limited’ produces some of the 
medicines locally from an ultra modern factory plant in Tongi and distributes them through 
its own wholesales and other members of the pharmaceutical distribution chain to make sure 
accessibility of good quality and efficacious medicines at affordable prices. Moreover, the 
Bangladesh pharmaceutical industry has challenges and constraints. Notable among them are 
under development of manufacturing capacity, growing threat of counterfeit and diverted 
medicines from Asia, weaknesses in implementation of intellectual property rights, focus of 
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local production on Over-the-Counter (OTC) medicines, inability for local manufacturers to 
produce essential medicines that meet standards for international tenders, poor 
pharmaceutical coverage for the majority of Bangladeshis, high concentration of retail 
pharmacies in major cities and rural areas, unmet professional human resource development 
and high mark-ups at every stage of the supply chain which tends to increase the price of 
medicines. Some of the challenges facing ‘Eskayef Bangladesh Limited’ include lack of 
funds for some expansion projects such as taking charge of its own pharmaceutical 
distribution chain and buying more vans to improve its distribution network. Also, lack of 
government subsidies on taxes for privately owned companies (for instance high utility bills) 
and high taxes on imported raw materials increases the cost of local production.  The sector 
needs adequate support from the government to develop the API park to make the medicine 
products more competitive in global markets. The establishment of central drug testing 
laboratory is also required to strictly maintain the high standards of medicine and a bio-
equivalence testing facility to the clinical testing which is prerequisite to register our products 
in the regulated markets.  Manufacturers also need an uninterrupted supply of power and gas 
to the production units and special economic zones for the pharma industry with tax benefits, 
collaboration between the industry and universities is required to promote research activities 
particularly in developing specialized drug delivery systems.  
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